Erilaisten hepatotoksisuustyyppien analyysi transkriptio- profiloinnilla by Lehtivaara, Maria Elina
MARIA LEHTIVAARA
Analysis of diﬀerent hepatotoxicity types by transcript proﬁling
Master of Science Thesis
Examiner: Professor Olli Yli-Harja
Examiner and topic approved in
the Faculty of Science and Environmen-
tal Engineering Council
meeting on 15 August 2012
II
TIIVISTELMÄ
TAMPEREEN TEKNILLINEN YLIOPISTO
Biotekniikan koulutusohjelma
Maria Lehtivaara: Erilaisten hepatotoksisuustyyppien analyysi transkriptio-
proﬁloinnilla
Diplomityö, 72 sivua, 22 liitesivua
Syyskuu 2012
Pääaine: Laskennallinen systeemibiologia
Tarkastajat: Olli Yli-Harja
Avainsanat: Hepatotoksisuus, varhaisen vaiheen lääkekehitys, transkriptioproﬁili, mikro-
sirun data-analyysi
Tutkimusprojektin tavoitteena oli selvittää, onko geenien ilmentymisen muutoksista
mahdollista tunnistaa erityyppisiä maksan kudospoikkeamia välittämättä niitä aiheut-
taneista toksiineista. Toisena tavoitteena oli tutkia, voitaisiinko geenimuutosdataa käyttää
tulevaisuudessa referenssinä ennustettaessa mahdollisia kudospoikkeamia potentiaalisilla
lääkeainemolekyyleillä käsitellyissä näytteissä. Tätä tarkoitusta varten käytettiin japani-
laisen toksikogenomiikkaprojektin tietokannan (TG-GATEs, julkaistu 25.2.2011) DNA-
sirudataa rotan maksasta in vivo mitatuista geeni-ilmentymistä. Mahdollisuutta käyttää
pienempiä annoksia ja lyhyempiä koeaikoja resurssien säästämiseksi tutkittiin vertailemalla
eri altistumisaikoja ja annoskokoja.
Eroja eri kudospoikkeamaryhmien välillä tutkittiin pääkomponenttianalysilla (PCA) ja
KNN ristiintestausmenetelmällä. Kunkin ryhmän normaalista poikkeavasti ilmentyneet
geenit ja näissä poikkeuksellisen usein esiintyneet geeniontologiat listattiin, ja geenilis-
toja vertailtiin ja tutkittiin tarkemmin toksisuuden syiden ja mekanismien selvittämiseksi.
Aika- ja annosvastetta analysoitiin samalla menetelmällä. Datan käyttöä kudosmuutosten
ennustamisessa tutkittiin suorittamalla joitakin vertailuja sekä tunnettujen että mahdol-
listen lääkeainekandidaattimolekyylien avulla.
Tutkimuksen teoriaosuudessa käsitellään DNA-sirujen tekniikkaa ja datan käsittelyä
sekä esitellään toksikogenomiikkaa alana sekä TG-GATEs -tietokantaa. Analyyseissa on
käytetty R-ohjelmointikieltä, Bioconductor-paketteja sekä Ingenuity IPA -ohjelmistoa. Rää-
tälöityjä CDF-tiedostoja analyysissa käytettiin mahdollisimman ajanmukaisten ja tarkko-
jen tulosten saamiseksi.
Tulokset osoittavat, että toiset kudosmuutosryhmät erottuvat kontrollinäytteistä parem-
min kuin toiset. Näytteiden hajontaa selittävät paitsi analyysin muuttujat (löydösten
vakavuus, altistusaika ja annoskoko) myös erilaiset muutoksia aiheuttavat mekanismit. Tu-
losten perusteella näyttää siltä, että geeni-ilmentymän muutoksia voitaisiin käyttää yhtenä
menetelmänä lääkeaineiden toksisuutta ja sen mekanismeja arvioitaessa. Annos- ja aika-
vastetta tutkittaessa huomattiin, että näytteitä tarvitaan tulevaisuudessakin eri annostuk-
sella ja eri altistusajalla tehdyistä kokeista, sillä pelkät yksittäiset datapisteet saattavat
geeni-ilmentymistä tutkittaessa olla harhaanjohtavia.
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The aim of this project was to study whether it is possible to identify histopathological
changes in liver based on gene expression proﬁles, regardless of the toxic causing the change.
Another goal of the project was to study whether gene expression data can be used as a
reference when predicting possible histopathologies in future samples treated with possible
drug candidates. For this purpose, data from in vivo microarray gene expression studies
of rat liver from Japanese Toxicogenomics Project database (TG-GATEs, published in
February 25, 2011) was used. Possibility of using smaller doses and shorter experiment
times in order to save resources was studied by comparing diﬀerent exposure times and
dose levels.
Separation between diﬀerent histopathological groups was studied using Principal Com-
ponent Analysis and K-nearest neighbor cross-validation. The diﬀerentially expressed
genes and enriched gene ontologies from each group were listed, and the gene lists were
studied further and compared to observe possible causes and mechanisms of toxicity. Time
and dose responses were analyzed similarly. Some comparisons using well-known and pos-
sible candidate drug molecules were made in order to test the predictive use of the data.
In the theory section microarray technology and data analysis are explained, and the
ﬁeld of toxicogenomics and TG-GATEs -database are presented based on articles from
scientiﬁc journals and books. Analyses are performed using R-language, Bioconductor-
packages and Ingenuity IPA -software. Customized CDF-ﬁles were used in analysis to
provide most current and accurate results.
It was noticed that while other histopathologies are clearly separated from the con-
trols, others are more spread out. Spreading is likely to be caused by number of diﬀerent
mechanisms causing the toxicity in some groups, but also due to diﬀerent analysis factors
(severities of the ﬁndings, exposure times and dose levels). It seems that the data and gene
expression proﬁles can be used as references when estimating possible toxicity of a drug
molecule and the mechanisms of it. Some dose and time response was noticed. Due to
the complex nature of gene expression, samples treated with diﬀerent doses and exposure
times are needed to see the direction of the development: single values from a single data
point can be misleading.
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ABBREVIATIONS AND NOTATIONS
ALT Alanine aminotransferase, often measured from blood
samples to get information of events taking place in liver.
ALP Alkaline phosphatase (see ALT).
AST Aspartate aminotransferase (see ALT).
BP Biological Process (term used in GO).
CC Cellular Component (term used in GO).
CDF Chip Description File (CDF) contains information about
the layout of the microarray chip used. It describes the
link between probes and probesets, and identiﬁes PM and
MM probes and control probes.
cDNA Complementary DNA, one-stranded DNA molecule syn-
thesized from mRNA with reverse transciption. Does not
contain introns.
CEL CEL ﬁles contain measured intensities and locations for
microarrays. Generated by the GCOS software.
CV Coeﬃcient of variation: the ratio of the standard devia-
tion to the mean.
DAT DAT ﬁle contains the scanned microarray image. Gener-
ated by the GCOS software.
DNA Deoxyribonucleic acid, molecule containing genetic infor-
mation.
EPA Environmental Protection Agency of United States.
FC Fold-change.
FDA Food and Drug Administration, agency in United States
supervising i.e. pharmaceutical drugs.
VIII
FDR False discovery rate control, a statistical method used in
multiple hypothesis testing to correct for multiple com-
parisons.
GCOS GeneChip Operating Software by Aﬀymetrix: used to
scan and save the image of the microarray (DAT-ﬁle) and
to compute the intensity values (CEL-ﬁle).
GGA Groung glass appearance, a term used in histopathology.
GO Gene Ontology: describes in which biological process, cel-
lular component or molecular function the gene is present.
HC Hiearchical clustering algorithm.
IPA Ingenuity Pathway Analysis.
KNN K-Nearest Neighbor classiﬁcation algorithm.
LDH Lactate dehydrogenase (see ALT).
MAQC MicroArray Quality Control Consortium evaluates mi-
croarrays, methods of using them and the data analysis
process.
MAS5.0 A microarray data analysis software by Aﬀymetrix.
MF Molecular Function (term used in GO).
MM Miss-match probe, used in Aﬀymetrix microarray chips
to detect unspeciﬁc binding. The sequence of the probe
is same as in PM probe, but one base in the middle of the
probe is changed.
mRNA Messenger-RNA, ribonucleic acid transcriped from DNA
in nucleus and translated into protein sequence in ribo-
somes.).
PCA Principal Component Analysis.
PCR Polymerase Chain Reaction, a biochemical technology
used to amplify small amounts of DNA.
IX
PM Perfect match probe, used in Aﬀymetrix microarray chips
to detect binding of cDNAs from a test sample.
R R -programming language.
RMA Robust Multiarray Analysis.
SNP Single-nucleotide polymorphism, DNA variation of single
nucleotide across the members of species.
TBIL Total bilirubin (see ALT).
TG-GATEs The gene expression database produced during the TGP
project of Japanese government and private pharmaceuti-
cal companies. Short for TG-Genomics-Assisted Toxicity
Evaluation system.
TGP Japanese Toxicogenomics Project, performed by National
Institute of Health Sciences, 15 pharmaceutical compa-
nies and the National Institute Biomedical Innovation
(NIBIO) in Japan.
UniGene UniGene is a internet tool that computationally identiﬁes
transcripts from the same locus, analyzes expression by
tissue, age, and health status, and reports related proteins
(protEST) and clone resources.
11. INTRODUCTION
In order to eliminate the potentially harmful chemicals at the early stage of the drug
development process, it would be extremely useful to be able to identify the molecular
changes caused by a toxic which is known to cause pathological changes in certain organs.
These molecular changes can be detected in gene expression proﬁles, protein synthesis and
metabolism of an organism. [69, 35, 67, 56]
Gene expression proﬁling can be deﬁned as measuring of the activity of genes in certain
cell(s). These measurements are usually done with microarrays, small chips containing
probes for each gene of interest. Gene expression activity reﬂects the situation in the
cells(s), since it is regulated based on the signals the cell receives. By regulating gene
expression the cell adjusts to the changed situation by producing diﬀerent amounts of
proteins that function for example as enzymes, signal molecules or building blocks of larger
complexes. Gene expression proﬁles can be considered as the most sensitive measure, and
therefore gene expression patterns caused by toxic chemicals are extensively studied. Data
generated by these toxicogenomics studies can be found in several large, publicly available
databases. [69, 35, 67, 56]
Toxicity is often studied by comparing samples treated with toxic compounds to controls
and hence predicting possible biomarkers of toxicity [68]. However, the comparison is then
done without actual knowledge about the phenotype of the samples, and this might cause
unwanted variation in the results. Thus, the comparison between known toxic conditions
(that is, the eﬀects of the toxin are seen on the phenotype for example as histopathological
ﬁndings) and controls should provide more reliable foundation for predictions.
The aim of this project is to study whether it is possible to identify histopathological
changes in liver based on gene expression proﬁles, regardless of the toxicant causing the
change. For this purpose, data from in vivo gene expression studies of rat liver from
TG-GATEs database [47] is used. The database contains microarray test results done
with 150 or so diﬀerent chemicals (most of which are medical drugs) and corresponding
control studies. Several dosages and exposure times were studied. Aﬀymetrix GeneChips
were used as microarrays. The livers of the test animals were also analyzed. Based on
these histopathological ﬁndings, the microarray results can be grouped, and the possible
congruence of the most severe and common pathological changes can be studied. [67, 69, 68]
Histopathological groups are studied by detecting the diﬀerentially expressed genes
between each histopathological group and the controls. These genes can then be analyzed
further based on their ontologies. Principal component analysis and k-nearest neighbor
classiﬁcation can be used to highlight the diﬀerences between the histopathological groups
and which histopathological groups are distinguishable from each other based on the gene
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expression data. Tools from Bioconductor-project [10] are used in these analyses, and
analysis codes are written in R-language [16]. Some of the gene lists generated using
Bioconductor and R were uploaded and analysed further using Ingenuity pathway analysis
(IPA, Ingenuity Systems, Redwood City, CA) [64]. Due to the diﬀerent grouping of the
microarray experiments, batch eﬀect correction is needed before analysis. Customized
CDF-ﬁles (provided by Microarray Laboratory of Molecular and Behavioral Neuroscience
Institute of University of Michigan) [45] are used in analysis to provide most current and
accurate results.
First, the theory behind microarrays and their analysis, and the ﬁeld of toxicogenomics
are presented. Current situation in the ﬁeld is brieﬂy outlined. Materials and methods
are described in detail. Results of the analyses are reported, and their possible use and
relevance is discussed together with other issues related to toxicogenomics and drug devel-
opment, as well as possible ideas for future studies.
32. THEORETICAL BACKGROUND
In this Chapter the ﬁeld of toxicogenomics and its use in drug development are described,
as well as the current situation in the ﬁeld. Microarray technologies as well as data analysis
methods and tools are presented in detail. Also the histopathological terms used in this
project are explained. Focus is in TG-GATEs database and Aﬀymetrix arrays due to their
central role in this project.
2.1 Toxicogenomics in Drug Development
The amount of new drugs that enter the pharmaceutical market is decreasing, even though
the technology is advancing: one estimation of the success rate of a new drug is 1 in 10
000. Some state that the reasons for this are more tight regulations and the diﬃculty of
clinical trials, but one important reason might be the inconsistency between preclinical and
clinical tests and results. Many drug candidates are dropped out due to their toxicity, and
thus eﬀective ways for testing possible toxicity are valuable to pharmaceutical research.
[69]
Toxicogenomics can be determined as a study of changes in gene expression caused by
a toxic substance. In modern drug development it is important to eliminate potentially
harmful drug candidates as early and cheaply as possible [39]. Modern high-throughput
techniques, such as microarrays, may oﬀer an opportunity to do this eﬀectively [39]. Here,
the toxicogenomics and ongoing projects in this ﬁeld are presented. Special attention is
given to Japanese Toxicogenomics Project (TGP) and its database (TG-GATEs) which is
used in this study.
2.1.1 Toxicogenomics
In the past it was common for drug development to contain considerable amounts of test,
where diﬀerent chemicals were used on animals carrying artiﬁcially caused diseases. Besides
ethical, time and money related problems, this method suﬀers from diﬀerences between test
animals and human targets. After the sequencing of genomes of many common test animals
and humans it has been possible to target the drug research on well-known molecular
processes. Despite of this, many drugs advance to later stages of development before their
toxicity is noticed. [67]
In order to eliminate the potentially harmful chemicals at the early stage of the drug de-
velopment process, it would be extremely useful to be able to identify the molecular changes
caused by a toxic known to cause pathological changes in certain organs. These molecular
changes can be detected in gene expression proﬁles, protein synthesis and metabolism of
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the organism. The ﬁrst mentioned can be considered as the most sensitive measure, and
therefore gene expression patterns caused by toxic chemicals are a widely studied ﬁeld.
The identiﬁcation of these predictive biomarkers for toxicity during the pre-clinical stages
of drug development is of great importance to pharmaceutical companies. [67]
Toxicogenomics is determined as the application of microarray technologies to toxicology
studies, and it is widely used in pharmaceutical studies to identify chemicals with potential
safety problems [35, 67]. Besides identifying biomarkers of toxicity in order to predict the
hazardous chemicals, it is also used to study the molecular mechanisms of toxicity [35, 67].
It provides understanding of molecular changes caused by a disease or a treatment [35],
and can be used to detect relationships between changes in gene expression and end-point
data (for example histopathological ﬁndings, clinical chemistry) [67]. One ultimate goal of
toxicogenomics is to aid in risk assessment together with more traditional methods used
in drug development [67].
Toxicogenomics is considerably cheap, easy and fast. It produces lots of data, and lots
of references and databases exist and are becoming available. Microarray methods and the
ways of reporting the data are being standardized. Food and Drug Administration of the
United States (FDA) has identiﬁed toxicogenomics as a key opportunity in advancing per-
sonalized medicine and together with Environmental Protection Agency (EPA) they have
presented guidance documents to encourage scientiﬁc research for using toxicogenomics
data in drug development, medical diagnostics and risk assessment. [56]
2.1.2 Ongoing projects
Due to vast amount of data generated by toxicogenomics studies, large and well-designed
databases are needed. The data is generated and presented in standardized format (MI-
AME, see Chapter 2.2.2), which allows for its eﬀective use. [67]
There are several public databases, such as Gene Expression Omnibus (GEO; www.ncbi.
nlm.nih.gov/geo), ArrayExpress (www.ebi.ac.uk/microarray-as/ae/), Center for Informa-
tion Biology Gene Expression (CIBEX; http://cibex.nig.ac.jp/), EDGE (http://edge.on-
cology.wisc.edu/edge3.php), Chemical Eﬀects in Biological Systems (CEBS; http://cebs.
niehs.nih.gov/cebs-browser/), dbZach (http://dbzach.fst.msu.edu) and Comparative Tox-
icogenomics Database (CTD; Laboratory; http://ctd.mdibl.org).
In addition there are few collaboration projects such as European InnoMed PredTox
(http://www.genedata.com/lp/innomed-predtox.html), American Liver Toxicity Biomarker
Study and Japanese Toxicogenomics Project (TGP; http://wwwtgp.nibio. go.jp/index-
e.html), which all are collaborations of pharmaceutical companies and academic institu-
tions. [67]
2.1.2.1 Japanese Toxicogenomics Project
The TGP was performed in 2002 − 2007 by National Institute of Health Sciences, 17
pharmaceutical companies and the National Institute Biomedical Innovation (NIBIO) in
Japan. The original name of the project was Construction of a forecasting system for drug
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safety based on the toxicogenomics technique and related basic studies. The actual work
was performed in NIBIO. The primary goal of the project was to create an extensive gene
expression database called TG- GATEs (Genomics-Assisted Toxicity Evaluation system)
using Aﬀymetrix GeneChips and 150 diﬀerent chemicals, most of which are medical drugs.
List of these compounds is presented in table 3.1 on page 25. [67, 69]
Rat, which is often used as model organism in toxicological studies, was used as a test
animal. The gene expression was measured from liver samples of the test animals, since
most toxic compounds aﬀect liver cells (hepatotoxicity). Also, liver has relatively homoge-
neous composition of diﬀerent cell types, and homogeneous samples mean less unwanted
variation in the gene expression measurements. Another organ used was the kidney. Both
in vivo and in vitro studies were performed. In this Chapter we focus on the liver in vivo
studies, as the data used in this project is from these studies. The aim of the project is to
perform same in vitro tests to human hepatocyte cells as well, so that interspecies bridging
could be considered. [67, 69]
In in vivo studies, the test animals were treated either with single dose or multiple
doses. In the single-dose study, testing was done in many diﬀerent time points and with
diﬀerent dose levels. In repeated-dose study there were many diﬀerent treatment periods
and diﬀerent dose levels. Body weight, general symptoms, hematology, blood biochem-
istry and organ weight were collected from each test animal. Besides the gene expression
analysis, histopathological examination was performed to liver and kidney samples. The
protocol used is described in more detail in Chapter 3.2. [67, 69]
At the moment, the TG-GATEs database is published, and it is publicly available at
http://toxico.nibio.go.jp/. Some of the data intended is still missing from the database.
The TGP has reached its second stage, TGP2. The goals of this continued project are
to ﬁnd genomic biomarkers for toxicity prediction, to discover bridging of diﬀerences be-
tween species (essentially between rat and human) and apply toxicogenomics and genomic
biomarkers as regulatory part in drug safety assessment. [67, 69]
2.2 Microarrays
Microarrays are a high-throughput biochemical technique used widely in gene expression
analyses. They were developed in early 1990s, and their scope and the techniques related
to them are continuously developed further. Currently, several thousand scientiﬁc articles
related to or using microarrays are published each year [15]. The technology, diﬀerent
types of arrays and the data analysis process are brieﬂy explained here. A closer look is
taken on the Aﬀymetrix arrays, which were used when creating the TG-GATEs database.
2.2.1 The Central Dogma of Biochemistry
A phenotype of an organism is determined by its genes. Each cell in an organism contains
the same set of genes in chromosomes that consist of deoxyribonucleic acid (DNA). (Some
exceptions exist: for example red blood cells do not contain DNA.) DNA is a long molecule
consisting of two complementary strands. These strands consist of several monomers which
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contain a pentose sugar part, a phosphate part and a nitrogenous base part, which can
be either adenine (A), thymine (T) cytosine (C) or guanine (G). These molecules in the
two strands pair up selectively to A-T and C-G pairs (Watson-Crick base pairing). The
order of these basepairs is called the gene sequence, and this sequence is responsible for
the behavior of a gene. DNA contains informative parts (exons) and parts that are not
used (introns). [46, 62, 73]
When a gene is expressed in a cell, it is ﬁrst transcribed to a mRNA (messenger ribonu-
cleic acid). The mRNA can be considered as a one-stranded version of DNA, with one
additional hydroxy (-OH) group in the pentose ring and thymine replaced by similar base
called uracil (U). Thus, the sequence of the DNA molecule is coded to mRNA molecule,
which is then transported out from the nucleus of the cell. The mRNA is spliced so that
only exon-parts of DNA-code remain. [46, 62, 73]
After this the mRNA can be translated to aminoacid sequence of a protein. Translation
takes place in ribosomes, and it is enabled by transfer RNAs (tRNA). One tRNA can bind
to three bases (a codon), and it carries one amino acid complementary to those three bases.
For example, codon CAG codes for glutamine (one of the 20 amino acids), ATG is the
start codon and TAA, TAG and TGA are stop codons. These codons are universal:
the same code applies in all species. [46, 62, 73]
The process of transcription and translation form the basis of the central dogma of
biochemistry (see Fig. 2.1). Proteins are then responsible for the behavior of cells as they
function for example as enzymes, signal molecules or building blocks of the cell. [46, 62, 73]
One must keep in mind that the situation is often much more complex than the straight
forward DNA-mRNA-protein-function -scheme described above and that there are many
exceptions. Instead, genes and proteins often form complex networks and aﬀect each others
behavior in many ways. Also the dynamics of transcription and translation as well as the
lifetimes of these compounds can vary. Therefore, a small change in the expression of
a certain gene can have a great inﬂuence on the cell, whereas an even larger change in
another gene's expression might have very little or no eﬀect on the cell. [46, 62, 73]
During transcription, alternative splicing takes place: from a single DNA strand, sev-
eral diﬀerent mRNAs can be produced be choosing diﬀerent exons. Some of the mRNA
molecules are never translated to proteins, and some mRNAs code for proteins that are
parts of larger protein complexes, so that the single protein is not functional on its own.
Many proteins also go through post-translational modiﬁcations before they are fully func-
tional. [46, 62, 73]
The expression process described above is often triggered by some signal coming to
the cell. These signals can be mediated via signal molecules such as hormones, and they
reﬂect the processes taking place in the environment of the cell or elsewhere in the organism.
Thus, the expression patterns (which represent the amount of diﬀerent mRNA molecules
produced in the cell) reﬂect the situation of the cell itself, the organ of which the cell is a
part of, and the whole organism. [46, 62, 73]
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Figure 2.1: Schematic illustration of the central dogma of biology.
2.2.2 Microarray Technology
The mRNA molecules can be isolated from a cell sample with biochemical methods. Since
mRNAs degrade easily, they need to be reversibly transcribed into single stranded DNA
and then ampliﬁed with automated polymerase chain reaction (PCR). Since the DNA
strands bind to each other speciﬁcally via the basepairing, appearance of a particular
DNA -sequence in a sample can be tested by allowing it to pair up with a short piece
of DNA with the complementary sequence (called as probe). By binding the probe to a
surface and labeling the DNAs in the sample with a dye, the binding can be discovered
visually. Microarray technology takes advantage of these basic biochemical methods. [46]
Microarrays are glass, silicon or plastic chips of few cm2 that can contain from hundred
to many thousands of test sites [25]. A test site is an area of 10-500 microns that contain
probes, which can be oligonucleotides (<50 bases long nucleotide chains) or larger DNA
or RNA fragments [25]. Probes are used as targets into which the reporter molecules are
hybridized. These probes are attached to the chip covalently or noncovalently by either
synthesizing them in situ or immobilizing them to the test sites [25].
After the hybridization and washing of the chip the reporter molecules are detected
using a signal generated by the binding of the molecule to the target. This signal can
be for example ﬂuorescent, chemiluminescent, colorimetric or a radioisotope. The chip is
scanned or imaged to save the signal patterns, and the resulting data is then analyzed [25].
When the slide is scanned, the scanner excites it with a laser and detects the resulting
photon emissions from the ﬂuorescently labeled molecules hybridized to the probes in the
slide. The detected photon emissions are converted to 16-bit intensity values. There are
several scanners available commercially. [54]
To avoid confusion and enable comparison between research work done in diﬀerent
groups, international standards have been developed by Microarray Gene Expression Data
(MGED) Society (http://www.mged.org). They have published the Minimum Information
About a Microarray Experiment (MIAME), which describes what kind of information
should at least be submitted with microarray results, and how should this information be
presented. [37]
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2.2.3 Diﬀerent Types of Microarrays
There are the two main types of microarrays: robotically spotted and in situ photolitho-
graphically hybridized arrays. The ﬁrst ones are sometimes referred as cDNA microarrays
because the nucleic acids immobilized to the chips used to be PCR ampliﬁed cDNAs from
libraries. The latter ones can be called as oligonucleotide arrays (or oligoarrays) because
they use several shorter oligonucleotides to represent a certain gene. These oligonucleotide
arrays are sometimes referred also as Aﬀymetrix arrays after the well-known commercial
manufacturer. Nowadays oligonucleotide arrays are also prepared with robotically, so these
terms can be slightly misleading. [37]
Spotted arrays use so-called comparative hybridization, which means that two samples
(i.e. control vs. experiment, healthy vs. diseased) are labeled with two diﬀerent dyes
(usually red and green ﬂuorescent dye) and then hybridized to the same array. Therefore
the color of the spot implies whether another sample had higher amount of the mRNA in
question (the spot is either red or green), or whether the expression levels were somewhat
equal in both samples (yellow spots). [37]
Oligonucleotide arrays use only one color for labels, and each sample is hybridized to a
separate array. Then the intensity of the spot reﬂects the level of gene expression, and the
comparison between the samples is made afterwards. In Fig. 2.2 the diﬀerence between
the use of spotted arrays and oligonucleotide arrays is presented. [37]
The diﬀerences in the array design are reﬂected to their analyses as well. In spotted
arrays the test sites are (as the name says) round in shape, whereas in oligoarrays they
are rectangular. This causes diﬀerent concerns to background adjustment during the anal-
ysis. With spotted arrays the possibly diﬀerent behavior of the labels needs to be taken
into account during the analysis. With oligonucleotide arrays the normalization between
diﬀerent arrays might be troublesome. Both techniques are troubled with unpredictable
diﬀerences in results due to the diﬀerent handling of arrays, samples and dyes. Since the
TG-GATEs database used in this project is build using Aﬀymetrix oligonucleotide arrays,
next chapter focuses on them. [26, 50]
2.2.3.1 Aﬀymetrix GeneChip arrays
There are several companies producing microarrays and related systems and applications.
Aﬀymetrix Inc. is one of them. Aﬀymetrix 1.6 cm2 Genechips are used by thousands
of researchers. They are manufactured with in situ photolithographic process, and they
diﬀer from red/green channel spotted arrays as they have only one channel and that the
test sites are rectangular in shape. Due to use of only one channel, only one sample can
be put on each slide; separate control slides are needed. Aﬀymetrix mass-produces arrays
for several organisms: human, mouse, rat, arabidopsis, Drosophila, yeast, zebraﬁsh, canine
and E. coli. [29]
In each test site of 24 x 24 µm there is a set of 11-20 pairs of probes with same sequence.
There are 106−107 copies of each probe. Each probe is (14-)25 bases in length. The probe
pairs contain a perfect match (PM) and a mismatch (MM) probe. MM probes have same
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Figure 2.2: Illustration showing the principles of two-colored spotted arrays (A) and single
color oligonucleotide arrays (B), such as Aﬀymetrix GeneChips.
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sequence as the PM probes, but the 13th (the middle) base is changed to its Watson-Crick
complement in order to measure non-speciﬁc binding (see Figure 2.3). [29, 54, 3]
Figure 2.3: A schematic illustration of probesets and MM and PM probes [3].
For analysis of the scanned microarray data, Aﬀymetrix has its own software tool:
GCOS (GeneChip Operating Software). This software saves the scanned image and com-
putes the intensity values. The scanned image is saved as .dat -ﬁle and the intensity data
computed from this image is saved as .cel -ﬁle. For each probe set, a Signal value and a
Detection call are computed. The Detection call classiﬁes the samples as present, absent or
marginal based on p-values. Signal value is calculated using the One-Step Tukeys Biweight
Estimate. These methods are described in more detail in Chapter 2.3.3.2 and in [1].
The Aﬀymetrix GeneChips also contain several probes for quality control: poly-A-
controls (genes dap, lys, phe, thr, and trp) can be used to monitor the entire target labeling
process and the genes BioB, bioC and bioD for monitoring the hybridization. For these
controls, there are Control Kits available, that can be used to create samples with spiked
concentrations of these genes. To assure RNA sample and assay quality, β-actin and
GAPDH are used as internal controls. Their signal values from the 3' probe sets and 5'
probe sets are compared: this value reﬂects the degradation of RNA. [1]
The Aﬀymetrix GeneChips were designed by Steve Fodor and colleagues in the early
1990s with the methods used by computer microchip manufacturers. To prepare an Aﬀy-
metrix GeneChip, the chip is ﬁrst modiﬁed with silane reagent to provide hydroxyalkyl
groups as initial synthesis sites, which are then extended with shielded linker groups.
With masks and exposition of the chip to light, those protecting groups can be selectively
removed. These un-protected groups can then be coupled with protected nucleoside phos-
phoramidite monomers, which can then again be coupled to the substrates using phospho-
ramidite DNA synthesis. These cycles of removing of the shielding photolabile molecules
and addition of nucleotides can be repeated, and thus any nucleotide sequences can be
build on the array. [25]
2.2.4 Applications
There are many applications for DNA microarrays. Usually these contain either gene ex-
pression analysis or screening for single nucleotide polymorphisms. Therefore microarrays
are used in basic molecular biology analyses and in genetic research, but also in ﬁelds such
as pharmacogenomics research, infectious and genetic disease and cancer diagnostics and
in forensic and genetic identiﬁcation purposes. Microarray technologies are likely to be
developed further and gain importance also in other ﬁelds due to their economical and
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Figure 2.4: A photo showing the size of a Aﬀymetrix GeneChip. [17]
high-throughput beneﬁts. [25]
2.3 Microarray Data Analysis
Microarrays are a high-throughput technique: they generate huge amounts of data in a
short amount of time. Hence eﬀective methods are needed for the data analysis, and
several diﬀerent methods have been developed lately for each step of the analysis. The
methods used can also have a great inﬂuence on the results. Here the basic steps of the
data analysis are described, focusing on (single color) oligonucleotide arrays used in this
project. Bioconductor -project is also introduced, and some basic statistics. [50]
2.3.1 Statistics
In this Chapter some basic statistics concepts are presented to cover the methods used in
the data analysis. In data analysis tasks one often compares two groups to see whether
they diﬀer. This brings one to the essential question in statistics: what is signiﬁcantly
diﬀerent?
To compare two hypotheses, a test statistic and the corresponding p-value are com-
puted. There are hundreds of statistical tests that can be used. Choice of the statistical
test depends on the number of groups to be compared: for two groups, t-test and Mann-
Whitney (U) -test are used most often. For more than two groups analysis of variance
(ANOVA) or Kruskal-Wallis test are often used. [27]
Hypothesis pair consists of null hypothesis H0 and alternative hypothesis H1: usually
H0 is decided to mean that there is no diﬀerence between the groups compared, and H1
that they do diﬀer. The p-value can be determined as the risk that we reject H0 when we
should not. Thus some relatively small cut-oﬀ for p-value is needed: usually 0.05 or 0.001
are used. Larger data can often cause smaller p-values. [27]
T-test compares the means of the two groups (Welsh's t-test). The test statistic T is
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Table 2.1: Example of a contingency table.
Diﬀerentially Normally Total
expressed genes expressed genes
Belongs to a b a + b
certain pathway
Does not belong c d c + d
to that pathway
Total a + c b + d a + b + c + d = n
computed as follows:
T =
Xi −Xj√
s2i
ni
+
s2j
nj
(2.1)
where Xi and Xj are the means of the two groups, s
2
i and s
2
i are the variances of the
groups and nj and nj are the number of samples in the groups. This test does not assume
that the variances of the groups are equal: if this assumption is made, student's t-test can
be used. Student's t-test is similar to Eq. 2.1, but the denominator is multiplied with s:
s =
√∑n1
i=1(x1i − x¯1)2 +
∑n2
i=1(x2i − x¯2)2
n1 + n2 − 2 (2.2)
ANOVA tests for signiﬁcant diﬀerence between means of several groups: if we are
comparing two groups with one-way ANOVA, the results will be same as with the t-test.
[27]
As the p-value presents the probability of falsely rejecting the null hypothesis, some
methods are developed to estimate the p-value cut-oﬀs, i.e. what is suﬃciently improb-
able. Perhaps the most used method for this is the false discovery rate (FDR). FDR
can be explained as the expected proportion of false positives among the diﬀerentially
expressed genes. One of the most used methods for this is the Benjamini and Hochberg
-correction. [5, 24]
Fisher's exact test is used to compute the probability of getting the observed data.
For this purpose, hypergeometric distribution is used. For a 2x2 contingency table (Table
2.1) the probability would be:
p =
(
a+b
a
)(
c+d
c
)(
n
a+c
) (2.3)
2.3.2 Bioconductor Project
Bioconductor (http://www.bioconductor.org) is an open source project for computational
biology. The project began in 2001, and the ﬁrst packages were released in 2002. The main
focus of the project is to deliver high-quality infrastructure and tools for expression analysis
in R. Bioconductor is an open development initiative, where the users are encouraged to
become developers. Some of the packages and functions that are used in this project are
2. Theoretical background 13
described here. [14]
2.3.3 Basic Steps
The data analysis process can be divided into three basic steps: image analysis, prepro-
cessing and normalization, and data harvesting. For each step, there are several possible
methods. Image analysis is often done with a special software provided by the manufac-
turer of the microarray, while rest of the steps are usually performed by the researcher.
[19, 27]
There are several opinions on which order the analysis steps should be taken [27]. In
Fig. 2.5 one possible data analysis pipeline is shown. In this project, this kind of work
ﬂow was followed.
Figure 2.5: Flow chart of a microarray data analysis process.
2.3.3.1 Image Analysis
The very ﬁrst step of data analysis after scanning of the slide is the image analysis. First,
a grid is ﬁtted over the image of the slide in order to separate the test sites from each
other. Some slides (i.e. Aﬀymetrix slides) contain alignment marks to make this easier.
After gridding, segmentation is performed to diﬀerentiate the background pixels from
the actual foreground pixels. There are diﬀerent methods for this, as well as for the
background correction. Usually coeﬃcients of variation (CV) are used to determine the
optimal outlines for the grids. For background correction the slide is divided to smaller
squares (16 by default in the Aﬀymetrix software), and the lowest 2 % of the intensity
values in this area are averaged and used as a background value on that area. [25, 54, 3]
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2.3.3.2 Preprocessing and Normalization
The choice of preprocessing method can have important eﬀect on the results, especially
with oligonucleotide expression arrays such as Aﬀymetrix GeneChips. Preprocessing can
be divided into three steps: background adjustment, normalization and summarization.
There are several functions available to perform each of these steps separately, and functions
combining all of them. [19]
There are three basic schemes for background correction: ideal mismatch -method,
MAS 5.0 background correction and RMA convolution. MAS 5.0 is an software by Aﬀy-
metrix [28, 3]. The background adjustment method used by MAS 5.0 is described above
in 2.3.3.1. Originally MAS 5.0 used also (log) PM-MM values as expression values, but
this was noticed to generate noise to observations with low signal strengths. [19, 49]
Ideal mismatch method uses the MM probes as originally intended by the developers
of the Aﬀymetrix CeneChip: their intensity values are subtracted from the values of PM
probes. However, since the MM value can often (about 30 % of the cases) be larger than PM
value, a speciﬁc background (SB) value is calculated (using one-step biweight algorithm) to
be used instead of MM value in these cases. Using SB we can determine the ideal mismatch
(IM):
IM =

MM when MM < PM
PM
2SB
when MM ≥ PM and SB > τc
PM
2τc/(1+(τc−SB)/τs when MM ≥ PM and SB ≤ τc
(2.4)
where τc and τs are constants for tuning contrast and scaling (default values are 0.03
and 10, respectively). The background correction is done by subtracting IM -value from
PM value (PM -IM). [19, 3]
RMA (Robust Multiarray Analysis) convolution, originally developed by Irizarry et al
[30] as a part of the RMA method, does not use MM probes at all. Because of this, the
variance of low abundance transcripts is reduced. Instead of using MM probes, the PM
values are corrected using a model for the distribution of probe intensities across the array:
Yijn = µin + αjn + εijn, where i = 1...I, j = 1...J, n = 1...n (2.5)
where αj a probe aﬃnity eﬀect, µi representing the log scale expression level for array i,
and εij representing an independent identically distributed error term with mean 0. Based
on this model, an adjustment equation can be written:
E(S‖Y ) = y) = a+ b φ(
a
b )− φ(y−ab )
Φ(ab ) + Φ(
y−a
b )− 1
(2.6)
where a = s− µ− σ2 and b = σ, (µ = mean and σ2 = variance). θ and Θ are standard
normal density and distribution functions. S stands for the exponential signal component
and Y for the observed intensity. [19, 49]
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Normalization is the term used for manipulation of data in order to make it more
comparable: microarray experiments usually contain multiple arrays, and it is of interest
to remove the non-biological sources of variation. Again, there are several methods. [6, 19]
Scaling method, used by Aﬀymetrix in their software, chooses one baseline array and
scales all the other arrays so that they have the same mean intensity as the baseline array.
Trimmed mean can also be used by removing the lowest and highest frequencies (usually
2% is removed from both ends). [19, 6]
Quantile normalization equalizes the probe intensity distributions between arrays in
a set of arrays. The method is named after the idea of quantile-quantile plot, where a
diagonal line can be seen if the two vectors plotted in it follow the same distribution. In
n dimensions we would see a straight line in
(
1√
n
, ..., 1√
n
)
. The algorithm used to project
the data points to the diagonal of the n dimensional quantile plot is the following:
1. Form matrix X with dimensions p × n (n is the number of arrays, p is
the length of the array), where each array is a column.
2. Sort each column of X to get Xsort
3. Compute the mean of each row and place this value to each element in
the row to get ´Xsort
4. To getXnormalized, rearrange each column of ´Xsort according to the order
in X.
This method can be varied by estimating the distributions smoothly, but it can be
noticed that the algorithm above performs rather well for high-density oligonucleotide
data such as Aﬀymetrix GeneChips. One problem in forcing the quantiles to be equal is
that in the tails there might be probes having the same values in all arrays. In practice this
is however unlikely, as the probesets expression is computed from multiple probe values.
[19, 6]
Another normalizing methods are cyclic loess, contrast normalization and non-linear
methods. The last-mentioned uses baseline array similar to scaling method, but the ad-
justments between arrays are non-linear [19, 6]. Cyclic loess normalizes arrays pairwise
(with two-channel data, the two channels form the pairs) as described by Yang et al. [74].
The cycle of the pairwise combinations is continued until convergence, so this method is
rather time-consuming. Contrast normalization method is faster and uses similar methods,
described in detail in [4]. [6, 19]
Summarization is the last stage of pre-processing when working with Aﬀymetrix data:
it is the process of combining the multiple probe intensities for each probeset to get an
expression value. Again, there are several methods available. Probably the most used way
to summarize the probe intensities is the median polish algorithm, used for example in RMA
-function.
Median polishing is an iterative procedure for extracting row and column eﬀects in a
two-way table using medians rather than means. In the algorithm, observations yi,j in a
two-way table follow a model:
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yi,j = µ+ αi + βj(+i,j) (2.7)
where µ represents a grand eﬀect, αi and βj denote the i :th row eﬀect and the j :th
column eﬀect. (i,j is the measurement error in the element (i, j).) In the least squares ﬁt,
these parameters are sought so that the row and column sums of the residuals are zero, but
as the name says, median polishing method uses medians instead. The algorithm updates
a table: 
e1,1 · · · a1,c a1
...
. . .
...
...
er,1 · · · er,c ar
b1 · · · br m
 (2.8)
where initially eij = yij , ai = bj = m = 0. When updating the table, condition
yij = m+ ai + bj + eij must hold. When updating the table, row and column sweeps are
alternated: a row sweep means that for each row the median of columns 1,... ,c is subtracted
from those columns and added to the last column, and vice versa for the columns sweep
(=for each column, the median of rows 1,...,r is subtracted from those rows and it is added
to the bottom row). These two steps are performed until the changes are considerably
small (under a certain limit). [70]
2.3.3.3 Batch Eﬀect
Microarray results can be aﬀected by slight changes in non-biological variables. Such
variables are for instance diﬀerent types or lots of chips, reagents from diﬀerent lots, diﬀer-
ent storage or shipment conditions of chips or reagents, washing conditions (temperature,
ionic strengths), scanner calibration, diﬀerent experimenters and changes in the environ-
ment (temperature, ozone levels) [11, 40]. Because of this, these variables are documented,
and those tests that are done with same parameters (at one site over a short period of time
using the same platform and experimenter) belong to same batch. [11]
The systematic error introduced when samples are processed in multiple batches is called
batch eﬀect. This error can be reduced by designing the experiments carefully, but the only
way to absolutely eliminate it is to perform all the tests in a single batch. Understandably
this is seldom possible with larger studies, and there are always some variables that are not
under the control of the researcher. Therefore there are several programs available that
can adjust the data according to the batches afterwards. [11]
However, according to [11], batch eﬀect is rarely taken care of: in January-June 2010
only 10 % of the published microarray data papers addressed this issue. The batch eﬀect
can account as much as 50% of the observed variation in expression [11], so by adjusting
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according to it the statistical power of the analysis can be increased and the underlying
biological phenomena can be detected [38]. With batch eﬀect correction it could in theory
be possible to compare and combine microarray data sets even from diﬀerent laboratories
[38].
2.3.3.4 Identifying Diﬀerentially Expressed Genes
The main goal in many microarray studies is to deﬁne the diﬀerentially expressed genes.
This means identiﬁcation of those genes whose expression patterns diﬀers according to
their phenotype, treatment or any experimental condition. Here, those genes which are
diﬀerentially expressed between control arrays and those arrays with histopathological
ﬁndings (=phenotypical changes) are of interest. [19]
When discussing about diﬀerentially expressed genes, a question of determinition arises:
what kind of value and cut-oﬀ should be used? An eﬀort to standardize these issues was
established by MicroArray Quality Control (MAQC) Consortium in 2006. MAQC is an
eﬀort managed by FDA (Food and Drug Administration of US) scientists and consisting of
over hundred researchers at 51 diﬀerent academic, government and commercial institutions.
The goals of MAQC is to evaluate microarrays, experiments done on them and the data
analysis process. A higher goal is to ﬁnd the ways and limits of how microarrays can be
used in decision making in regulatory aﬀairs (such as drug selling licenses) and in the clinic.
[15, 55, 56]
MAQC states in their publication [56] that often the statistical signiﬁcance (represented
by p-value) alone is used to determine the degree of diﬀerential expression, which has caused
disagreement. Therefore they propose that also the actual measured quantity of diﬀerential
expression (= fold change) should be used in identiﬁcation. In their own studies, they use
the following criteria: p-value < 0.001 and a mean diﬀerence greater than or equal to
twofold. [56]
Use of pure fold change as a criteria is criticized, especially with a small dataset with only
a few replicates, as it does not take into account the biological and experimental variation,
which varies from gene to gene [19, 31]. This means that distributions of expression levels
are not always normally distributed and that the distributions may vary from gene to gene
[58]. Therefore there are several statistical tests available for more clever analysis. Some
of these methods were compared by I. Jeﬀery et al. in [31], where they state that the
Empirical Bayes statistic, the Area Under the ROC curve -method and Rank products are
the most accurate ways for identiﬁcation of diﬀerentially expressed genes, and that these
methods produce the most robust classiﬁers.
For linear modeling of the expression of each gene, Bioconductor has a package called
limma. Usually the analysis of diﬀerential expression begins by ﬁtting a linear model
(function lmFit does this), which can be used to estimate the variability of the data and
to distinguish the random variation. For this, a design matrix is needed. This matrix
describes the diﬀerence of the RNA targets in each array, for example which arrays are
controls and which are the test group. Hence each row in the design matrix corresponds to
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an array and each column to a diﬀerent source of RNA: in the example case, there would
be two columns (controls and tests). Contrast matrix then again determines the wanted
comparisons (=contrasts) between the coeﬃcients: in the example case the comparison of
interest would be as simple as disease-control. This simple comparison is equivalent to a
one-way ANOVA (analysis of variance) for comparing two groups. [19, 58]
The linear model can be mathematically expressed as:
E
[
yj
]
= Xαj (2.9)
where yj is the expression data for gene j, X is the design matrix, αj is the vector of
coeﬃcients. The contrasts of coeﬃcients with biological interest are:
βj = C
Tαj (2.10)
where C is the contrast matrix. After lmFit, the next step is usually to use function
contrasts.fit, which computes estimated coeﬃcients and standard errors for a given set
of contrasts. The idea is then to test the null hypothesis of βj = 0. [19, 58]
The third step of an usual analysis is to use eBayes function to compute the moderated
t-statistics, moderated F-statistic, and log-odds of diﬀerential expression. The function
uses empirical Bayes shrinkage of the standard deviations of the probes towards a common
value, which is done by including data for genes that are expressed at similar levels. [19, 58]
Thus, the moderated t-statistic is similar to a normal t-statistic, except that the stan-
dard errors have been shrunk towards a common value: it can be said that information
is borrowed from the entity of genes. Therefore also the p-values computed from these
t-statistics are a bit diﬀerent, as they have more degrees of freedom. Log-odds present
the probability of a gene to be diﬀerentially expressed, so that log-odd of zero means that
there is a 50:50 change that the gene is diﬀerentially expressed. The moderated F-statistic
combines t-statistic for all the contrasts into an overall test of signiﬁcance of that gene.
[19, 58]
The ﬁnal step is to adjust the p-values. Function topTable contains several methods
for the p-value correction. Most commonly used is the Benjamini and Hochberg -method
[5], which is considered to give a good compromise between sensitivity and speciﬁcity. The
method controls the false discovery rate (FDR, the expected proportion of false discoveries
amongst the rejected hypotheses). [19, 58]
fit <- lmFit(Dataset, design)
contrast_matrix <- makeContrasts(disease-control, levels=design)
fit2 <- contrasts.fit(fit, contrasts_matrix)
fit3 <- eBayes(fit2)
results <- topTable(fit3, number = dim(Dataset)[1])
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2.3.3.5 Gene Ontology enrichment
After determining the diﬀerentially expressed genes, one would usually like to know how
they are related or connected to each other. This knowledge should make it easier to
understand the biological phenomena taking place in the diﬀerent experiments. One way
to do this is by using Gene Enrichment Analysis and Hypergeometric tests.
Most eucaryotic organisms have same genes that control the biological core functions,
and hence the biological knowledge can be transferred to other organisms as well. Thus it
was inevitable to gather all the constantly changing and increasing knowledge about gene
and protein roles in to a database: this was done by Gene Ontology (GO) Consortium.
They determined three independent ontologies: biological process (BP), molecular function
(MF) and cellular component (CC). [66, 48]
These terms form a tree of nodes: for each lower level term there is a higher level term.
BP refers to a biological objective in which the gene is involved: a process often involves
chemical or physical transformations, and contains one or more molecular functions. Ex-
amples of BP terms are cell growth and maintenance (higher level) and translation
(lower level). Molecular function is deﬁned as the biochemical activity of a gene product.
Examples are enzyme, ligand (higher level) and adenylate cyclase (lower level). Cel-
lular component indicates the place in the cell where a gene product is active. Example
terms are nuclear membrane and Golgi apparatus. [66, 48]
The question in gene enrichment is: do the diﬀerentially expressed genes belong to same
gene ontology category? This issue can be solved with probabilities, i.e. by telling how
likely it is that in a certain GO category there are this many interesting genes. Based on
this, p-values are computed. Hypergeometric distribution is used to model the number of
interesting genes in the GO category. This test is often called as Fisher's exact test.[24]
For this test, one has to determine the universe of genes. The choice of the universe has
of course eﬀect on the p-values: in [24] it is recommended to use all possibly interesting
genes as universe. This can mean the genes that were present on the slide, or the genes
that have probes on the slide. The list of interesting genes is also needed, i.e. those genes
that were diﬀerentially expressed (see section 2.3.3.4). Genes that are presented by more
than one probe can cause problems in the analysis, and for the analysis to be functional,
only one value per gene has to be chosen. [24]
With Bioconductor, Hypergeometric testing is performed with hyperGTest -function.
The parameters are given to hyperGTest as a set called GOHyperGParams. The parameters
are: gene universe, list of interesting genes, annotation data package used, which ontology
to use (BP, CC, MF), p-value cut-oﬀ and the test direction (over or underpresentation of
the GO terms). As a result, hyperGTest returns an object (called HyperGResult), which
can be viewed as a summary, or which can be generated into a html -report including links
to Gene Ontology -webpage [48, 8].
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2.3.3.6 KNN
K-nearest neighbors (KNN) is a simple classifying algorithm, which classiﬁes a sample based
on the class of those k samples that are its nearest neighbors (if k=1, the classiﬁcation
is done based on the nearest neighbor). The neighbors with known class are called as
training examples: they are usually vectors with one feature in each element and with a
certain class label. For example, with gene expression data, each array can be considered
as a sample and the probe values are its features. Ergo, a sample with unknown class is
classiﬁed in the same class with those samples that have the most similar gene expression
values (see Fig. 2.6). [61]
There are several methods for selecting the distance metric, i.e. the measure that
describes how similar two samples are. Usually the simplest option, Euclidean distance, is
used:
d(a, b) =
√
(a1 − b1)2 + (a2 − b2)2 + · · ·+ (an − bn)2 (2.11)
For KNN, a training data set is needed. To test how well a set of samples can be
classiﬁed when their real class is known, cross-validation can be used. This means that
one at a time each sample is classiﬁed using rest of the samples as training examples. In
Bioconductor, knn1 -function and knn.cv -functions can be used to perform classiﬁcation
with a certain training set and by cross-validation. [52, 61]
If the classiﬁcation is done between two groups (for example diseased and healthy),
accuracy, precision, sensitivity and speciﬁcity of the classiﬁcation can be computed by
comparing the classiﬁcation results to the known, true classes:
accuracy =
TP + TN
TP + FP + FN + TN
(2.12)
precision =
TP
TP + FP
(2.13)
sensitivity =
TP
TP + FN
(2.14)
precision =
TN
TN + FP
(2.15)
where TP = number of true positives, TN = number of true negatives, FP = false
positives and FN = false negatives. In the example one has negative = healthy and
positive = diseased. [61]
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Figure 2.6: Principle of KNN classiﬁcation.
2.3.3.7 PCA
Principal component analysis (PCA) is a simple, non-parametric method for extracting
relevant information from data sets. PCA was invented in 1901 by Karl Pearson. The goal
of PCA is to ﬁnd those components or surfaces in space that show the highest variance
when the data is projected to them. PCA arranges the components of the datamatrix
according to their eigenvalues. [57, 61, 41]
The ﬁrst principal component has the largest possible variance, and the following compo-
nents have highest possible variance under the constraint that they need to be uncorrelated
with the preceding components. By using only the ﬁrst two or three principal components
as axis in a plot and presenting the dataset as coordinate points on these axes, the data
can be viewed in a sense from the most informative viewpoint. Therefore PCA is a useful
tool when one wishes to visualize multidimensional data. [57, 61, 41]
PCA can be performed with a prcomp function from the stats package in R. The
calculation is done by a singular value decomposition of the (centered and possibly scaled)
data matrix, (not by using eigen on the covariance matrix.) [57, 70]
pc = prcomp(t(exprs(Data)))
2.4 Histopathology
Liver is very central to the metabolism of most foreign substances. The most frequent
reason for the withdrawal of an approved drug from the market is stated to be drug-
induced injury in liver (hepatotoxicity) [36]. Most drugs are lipophilic, which means that
they can cross the membranes of intestinal cells. In the hepatocytes, they are transformed
into more hydrophilic form, and may be excreted in urine or bile. This biochemical route
includes oxidative pathways and transport proteins. [36]
Due to the central role of liver, toxicology studies usually include histopathological
studies of liver. These studies were also performed in the Japanese Toxicogenomics Project
(TGP). The most common histopathological ﬁndigs in rat liver samples in TGP were hyper-
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Table 2.2: Levels of the terms used to describe the pathological ﬁndings in TGP.
This grouping (blue) is used in the analysis.
• Hypertrophy
• Necrosis
• Cellular inﬁltration
• Inﬁltration of
mononuclear
cells
• Inﬁltration of
lymphocytes
• Microgranuloma
• GGA
• Vacuolar degenera-
tion• Granular degen-
eration
• Vacuolization
• Vacuolar
degenera-
tion
• Fatty de-
generation
• Cellular change
• Asidophilic
• Basophilic
• Eosinophilic
• Cellular foci
trophy, cellular inﬁltration and foci, microgranulomas, ground glass appearance, necrosis,
degenerations and basophilic, eosinophilic and asidophilic changes (see Table 2.2). The
procedure used in TGP is described in a more detailed manner in section 3.2.5. [69]
Hypertrophy is the additional development of a cell (or an entire organ) due to increase
in the bulk material; the size of the cell(s) increase. Necrosis means the death of cell(s) in
a certain area due to some external stimulus, for example due to lack of blood circulation,
frost or disease. [32]
Cellular inﬁltration means migration and accumulation of cells within the tissues. It
might also be due to excess multiplication of cells. In TG-GATEs database the histopatho-
logical ﬁndings of cellular inﬁltration of mononuclear cells and lymphocytes were marked
separately. Microgranulomas are small collections of accumulated macrophages. Ground
glass appearance (GGA) refers to uniform, ﬁnely granular cytoplasm with a peripheral clear
halo. In liver, GGA occurs in the cytoplasm of liver cells due to the swelling of smooth
endoplasmic reticulum. [32]
Degeneration can be determined as impairment or loss of the function and structure of
cells or tissues, often leading to death of the involved part. Vacuolar degeneration means
the formation of vacuoles in cytoplasm, most frequently due to accumulation of fat or water
by cloudy swelling. Fatty degeneration (=steatosis, suom. rasvamaksa) is the accumulation
of excess lipids in vesicles. In granular (eosinophilic) degeneration, intracellular water is
accumulated in cells. Vacuolization means formation of any kind of vacuole in the cells.
As these terms refer to similar events, in the analysis they are considered to belong into a
larger group called as vacuolar degeneration.
Basophilic, eosinophilic or asidophilic change is a term describing the change in appear-
ance of certain cells when staining them with diﬀerent dyes. Basophilic cells take up basic
dyes, and thus changes in for example nucleic acid concentrations are reﬂected. Eosin
on the other hand is an acidic dye, and therefore changes in basic structures are seen.
Asidophilic staining also uses acidic dyes. Cellular foci is a region of a localized bodily
infection or disease, and was also used in TGP to mark cellular changes. All these ﬁndings
were considered in the analysis as cellular change. [32]
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3. METHODS AND MATERIALS
In this project, R -programming language and Bioconductor -packages were used to analyze
selected microarray data available in TG-GATEs database. Some gene lists produced with
Bioconductor -packages and R were also studied with Ingenuity Pathway Analysis tools.
Customized CDF-ﬁles and several existing tools were used. Here the used softwares, data
and analyzing tools and methods are described in detailed manner.
3.1 Softwares
The data analysis was executed in R, and several Bioconductor -packages were used as
analyzing tools. The version of R used in this project is 2.15, and most of the packages
used in the project are from the latest release of Bioconductor (version is 2.10). The codes
needed for the analysis were written in R as separate functions. Some of the data was also
analyzed using Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood City, CA)
software.
R is a coding language for statistical computing and graphics. It is based on the S
project, and was initially written by Robert Gentleman and Ross Ihaka from Statistics
Department of the University of Auckland. R is available as Free Software, and can be
downloaded from http://www.r-project.org/. [16]
Bioconductor is an open source and open development software project aiming to de-
velop tools for the analysis of high-throughput genomic data, for example microarray data.
It is based on the R programming language. The project was initiated in 2001, and it is
supervised by the Fred Hutchinson Cancer Research Center. Bioconductor packages can
be downloaded from http://www.bioconductor.org/. [20]
Ingenuity Pathway Analysis (IPA) was used to analyze and organize the gene lists of
diﬀerent samples which were ﬁrst generated using R and Bioconductor. The knowledge
of pathways, network and other interactions along with relationships between diﬀerent
molecules and states that were deﬁned in the Ingenuity Knowledge Base were used widely.
The Knowledge Base is a repository of biological interactions and functional annotations
created from millions of individually modeled relationships between proteins, genes, com-
plexes, cells, tissues, metabolites, drugs, and diseases [63]. These ﬁndings are linked to the
original source of information (scientiﬁc article), manually reviewed and updated weekly.
The terms and deﬁnitions are somewhat unique to the database. [64, 63]
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3.2 Data
In this project we used rat liver in vivo gene expression data from Japanese TG-GATEs
database (see 2.1.2.1 for more details) which has been publicly available since February 25,
2011. Here we describe the used data more closely.
3.2.1 Test Organisms
As mentioned in 2.1.2.1, rat was used as a model organism for the analyses in TG-GATEs.
The rats were six weeks old male Sprague-Dawley rats. In each treatment group there were
ﬁve rats. In the repeated dose in vivo study, results of which are used in this project, the
rats were treated with the drug once a day for 3, 7, 14 or 28 days. For controls, the same
amount of rats were treated similarly but only the vehicle was given to them. [67]
Drugs were given orally in most cases and intravenously in few cases. Vehicle used for
oral route was either 0.5% Methylcellulose or corn oil, and for intravenous route it was either
saline or 5/5 glucose solution. There were three diﬀerent dosages: low, middle and high,
mainly with ratios of 1:3:10. Usually the lowest dose corresponds to the pharmacological
dose. [67]
Rats were sacriﬁced 24 h after the last dose, after which their body weight, liver
and kidney weight, food consumption, hematology and blood biochemistry were stud-
ied. Histopathology of liver and kidney were also examined. Gene expression analysis was
performed on three rats from each group. In 2006, it was estimated that data will be
collected from 24 000 rats. [68, 67]
3.2.2 Compounds
The compounds used in testing were mainly well known medical compounds such as aspirin,
diazepam and ibuprofen. The compounds were chosen to cover most of the therapeutic cat-
egories (such as CNS, anti-inﬂammatory, cardiovascular, metabolic etc.), excluding those
that are not suitable for transcriptome analysis from either liver or kidney (such as derma-
tological drugs) and anti-cancer drugs, whose toxicity to liver or kidney is not a primary
problem.
There were 150 diﬀerent compounds in the database during the project. Some of the
compounds were supplied by the companies that were members of the project. With-
drawn drug candidates from the member companies of the project were also studied. The
compounds are listed in table 3.1. [68]
3.2.3 Procedure
Immediately after the sacriﬁce of the test animal, a sample of about 30 mg was taken from
the left lateral lobe of the liver. The sample was stored in RNA later (Ambion, Austin,
TX, USA) overnight at −4oC. The RNA was isolated with RNeasy kit by Bio Robot 3000
(Qiagen, Valencia, CA, USA). Samples were homogenizated with Mill Mixer (Qiagen) and
zirconium beads, and the purity of the samples was tested with gel electrophoresis. [65]
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Table 3.1: The compounds studied in TG-GATEs database.
Acetaminophen
Acetazolamide
Ajmaline
Allopurinol
Allyl alcohol
Carbamazepine
Carbon tetrachloride
Carboplatin
Cephalothin sodium
Chloramphenicol
Chlormadinone acetate
Chlormezanone
Chlorpromazine hydro-
chloride
Chlorpropamide
Cimetidine
Ciproﬂoxacin hydrochlo-
ride
Cisplatin
Cloﬁbrate
Clomipramine hydro-
chloride
Colchicine
Coumarin
Cyclophosphamide
monohydrate
Cyclosporine A
Danazol
Dantrolene sodium
Hemiheptahydrate
Diazepam
Diclofenac sodium
Diltiazem hydrochloride
Disopyramide
Disulﬁram
DL-ethionine
Doxepin hydrochloride
Doxorubicin hydrochlo-
ride
D-Penicillamine
Enalapril maleate
Erythromycin ethylsucci-
nate
Ethambutol dihydrochlo-
ride
Ethanol
Ethionamide
Etoposide
Famotidine
Fenoﬁbrate
Fluphenazine dihydro-
chloride
Flutamide
Furosemide
Gemﬁbrozil
entamicin sulfate
Glibenclamide
Griseofulvin
Haloperidol
Hexachlorobenzene
Hydroxyzine dihydro-
chloride
Ibuprofen
Imipramine hydrochlo-
ride
Indomethacin
Iproniazid phosphate
Isoniazid
Ketoconazole
Labetalol hydrochloride
Lomustine
Lornoxicam
Mefenamic acid
Meloxicam
Metformin hydrochloride
Methapyrilene hydro-
chloride
Methimazole
Methotrexate
Methyldopa
Methyltestosterone
Mexiletine hydrochloride
Monocrotaline
Moxisylyte hydrochloride
Naproxen
Nicotinic acid
Nifedipine
Nimesulide
Nitrofurantoin
Nitrofurazone
N-nitrosodiethylamine
N-phenylanthranilic acid
Omeprazole
Papaverine hydrochlo-
ride
Pemoline
Perhexiline maleate
Phenacetin
Phenobarbital sodium
Phenylbutazone
Phenytoin
Promethazine hydrochlo-
ride
Propylthiouracil
Puromycin aminonucleo-
side
Quinidine sulfate
Ranitidine hydrochloride
Rifampicin
Simvastatin
Sodium valproate
Sulfasalazine
Sulindac
Tacrine hydrochloride
Tamoxifen citrate
Tannic acid
Terbinaﬁne hydrochlo-
ride
Tetracycline hydrochlo-
ride
Theophylline
Thioacetamide
Thioridazine hydrochlo-
ride
Ticlopidine hydrochlo-
ride
Tiopronin
Tolbutamide
Triamterene
Triazolam
Trimethadione
Vancomycin hydrochlo-
ride
Vitamin A
WY-14,643
(7)-Chlorpheniramine
maleate
(7)-Sulpiride
17-alpha-Ethinyl estra-
diol
2-Acetamidoﬂuorene
2-Bromoethylamine hy-
drobromide
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Microarray analysis was performed to 3 of the 5 samples using either rat230A or rat230.2
GeneChip probe arrays (Aﬀymetrix, Santa Clara, CA, USA). The procedure used was
based on the manufacturer's instructions. For cDNA synthesis, Superscript Choice System
(Invitrogen, Carlsbad, CA, USA) and T7-(dT)24-oligonucleotide primer (Aﬀymetrix) were
used. cDNA Cleanup Module (Aﬀymetrix) was used for puriﬁcation of the cDNA. To syn-
thesize biotin-labeled cRNA, RNATranscript Labeling Kit (Enzo Diagnostics, Farmingdale,
NY, USA) was used. [65]
Hybridization of fragmented cRNA (10 µg) to the probe array was performed at 45o C
at 60 rpm and it took 18 h. After hybridization, the arrays were ﬁrst washed and then
stained with streptavidin-phycoerythrin (Fluidics Station 400 by Aﬀymetrix was used). For
scanning, Gene Array Scanner by Aﬀymetrix was used. For image processing, Aﬀymetrix
Microarray Suite version 5.0 (MAS 5.0) was used. Per chip normalization was performed
by setting the mean intensity to 500. [65]
3.2.4 Aﬀymetrix GeneChip: Rat Genome 230 2.0 Array
The general principles of Aﬀymetrix GeneChip arrays are presented in 2.2.3.1. Aﬀymetrix
GeneChip Rat Genome 230 2.0 Array is a whole-genome array that has 31,000 probe sets
that can be used to analyze expression of over 30,000 transcripts from over 28,000 well
tested genes. Sequences used to design the array were selected from GenBank, dbEST and
RefSeq. The sequence clusters were created based on UniGene database, and developed
further by comparing them to the draft assembly of rat genome from the Baylor College
of Medicine Human Genome Sequencing Center. [2]
The oligonucleotide probes complementary to each sequence are synthesized to the
array in situ. Each sequence is represented by 11 pairs of oligonucleotide probes. A set
of rat maintenance genes are included in the array for normalization and scaling of the
experiments. [2]
3.2.5 Histopathological Analysis
After the sacriﬁcation of the rats, their livers were quickly removed, and sections of them
were placed to 10% phosphate-buﬀered formalin. These formalin-ﬁxed sections were then
embedded in paraﬃn, and stained witht hematoxylin and eosin. Then the samples were
examined with light microscopy. [39, 67]
Each sample was analyzed by two trained pathologists. They graded the ﬁndings to no
change, minimal, slight, moderate and severe. In ﬁgure 3.1 for example periportal necrosis
was detected. [39, 67]
3.2.6 Blood Biochemistry
Several concentrations were measured from the blood samples (collected from the abdom-
inal aorta). These include: alanine aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), total bilirubin (TBIL) and Lactate dehydrogenase
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Figure 3.1: Example of histopathological sample from TG-GATEs. Slight periportal necro-
sis was detected from this sample of a rat that had been given 30mg/kg of allyl alcohol for
15 days.
(LDH). All these values are used in medical examination to predict liver damage or mal-
function. [22]
Alanine transaminase (ALT), also called serum glutamic pyruvate transaminase (SGPT)
or alanine aminotransferase (ALAT) is an enzyme present in hepatocytes. Aspartate
transaminase (AST), also called serum glutamic oxaloacetic transaminase (SGOT) or as-
partate aminotransferase (ASAT), is similar to ALT as it is another enzyme associated
with hepatocytes. AST value is not that speciﬁc to liver damage. [22]
Alkaline phosphatase (ALP) is a protein found in all tissues, but especially in high levels
in the liver, bile ducts, and bone. ALP is a hydrolase enzyme which removes phosphate
groups from many types of molecules (such as nucleotides and proteins). Lactate dehydro-
genase (LDH) is an enzyme found in many body tissues, including the liver. Bilirubin is a
yellowish pigment found in bile, which liver helps to break down. [22]
3.2.7 Arrangement of the Data into Histopathological Groups
For the analysis, the data was grouped based on the histopathological ﬁndings from each
array. For this purpose we used a table with all the necessary information about the arrays
reported in TG-GATEs. The table contained following information about each array: the
barcode, the batch number, used chemical, dose, dose level (control, low, middle, high),
exposure time (3, 7, 14, 28) and the most severe histopathological ﬁnding and its grade
(minimal, slight, moderate, severe). If there were several ﬁndings with equal severity,
alphabetical order was used to decide which term to use.
Based on this, we chose few of the most common ﬁndings as described in Chapter 2.4,
and grouped the ﬁles according to them. Table 3.2 shows the number of samples found in
each group. All the available tests done with vehicles were used as controls.
To analyze the dose response, the data was arranged a bit diﬀerently: ﬁrst, those
samples with a certain histopathological ﬁnding and treated with the highest dose were
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Table 3.2: The most common histopathological ﬁndings and amount of samples in each
group.
(Histopathological) group Number of samples
Hypertrophy 442
Necrosis 77
Cellular change 124
Cellular inﬁltration 344
Vacuolar degeneration 173
Controls (without ﬁndings) 1392
Treated, but no phenotypical ﬁnding 3621
Other ﬁndings 591
Total number of samples 6765
chosen for each group (high dose -group). Next, the compounds found in each group,
i.e. causing a certain phenotype, were determined. Then the compounds which caused
this certain phenotype in more than ﬁve samples were chosen (see Fig. 4.12), and those
samples treated with the same compound but with middle or low dose, and which show
nothing in the phenotype (=no pathological ﬁndings reported), were chosen as the other
two groups (middle dose and low dose).
The deviation of diﬀerent compounds causing diﬀerent phenotypes can be seen in Fig.
4.12. Note that for example necrosis is not caused by any particular compounds alone, but
is found from many groups. In all the cases, there were some ﬁndings in controls as well,
but these were not used for the analysis.
Similar analysis was attempted for the diﬀerent exposure times using only the highest
dose, but there was enough data only if the two latest time points (28 and 14 days) and
the two earliest time points (3 and 7 days) were combined. Even with these conditions,
only one group (hypertrophy) contained enough data for reliable analysis.
3.3 Analysis Methods
As mentioned in 2.3, there are several options for each step of microarray data analysis.
In the same chapter the principles of diﬀerent methods were brieﬂy discussed. Here we
describe which methods were used in this project to analyze the previously described data.
3.3.1 Preprocessing
Before the actual data analysis steps, the data was ﬁrst loaded to R and preprocessed, and
batch eﬀect correction and some ﬁltering steps were performed. Here these procedures are
described more closely. Also the Chip Description Files (CDF) used are presented here.
3.3.1.1 Preprocessing: justRMA
The data was downloaded from TG-GATEs as .CEL -ﬁles, which contain one single rep-
resentative intensity value for each feature [13]. There were 6765 of these ﬁles (32.6 GB),
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Figure 3.2: Diﬀerent compounds causing certain histopathological ﬁndings with high dose.
For further analysis, only those compounds causing certain ﬁnding in more than ﬁve sam-
ples were considered (blue line).
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so an eﬀective function was needed to load them to R for the analysis. Thus a function
called justRMA was used to read the CEL ﬁles and to simultaneosly perform preprocessing
of the ﬁles. It can be said that justRMA combines ReadAffy and rma -fucntions. [18, 51]
The justRMA -function performs normalization using quantile normalization. For back-
ground correction it uses RMA correction. Both methods are described in section 2.3.3.2.
The CDF-ﬁles were given as a parameter to the function. Output of the function is an
ExpressionSet -object. [18, 51]
3.3.1.2 Filtering
After normalization of the data, non-speciﬁc ﬁltering was performed to reduce the amount
of the data and to make the computations less time-consuming. Those probesets that
show little variation across all the samples were ﬁltered out, as they do not contain any
valuable information. First, the coeﬃcient of variability (CV = standard deviation / mean)
were computed for each probeset. By using CV -values instead of just standard deviations
makes ﬁltering less sensitive to intensity related bias. It was chosen to include 10% of the
genes with highest variabilty (see Figure 3.3). With nsFilter function, control probes
were ﬁltered using the AFFX - preﬁx in their name.
Figure 3.3: Histogram showing the ﬁltering according to coeﬃcients of variability. Blue
line shows the 10% cut-oﬀ used for ﬁltering.
3.3.1.3 Batch Eﬀect Correction
In the data used in this project, the batches usually contained some or all of the experiments
with same compound and same exposure time (that is, for example all 3 days experiments
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Figure 3.4: Illustration of the principle of the batch eﬀect correction used in this project.
done with aspirin with diﬀerent doses, including the controls). Because we organized the
data based on the histopathological ﬁndings and thus mixed together ﬁles from experiments
with diﬀerent compounds, exposure times and dosages, a special batch eﬀect correction
was needed. For this purpose, a special R-script was written.
The idea behind the batch eﬀect correction script is that all the gene values in each
control group should in theory be at the same level (lets call this the zero level): an
assumption is made that all the variation between the diﬀerent controls is due to the batch
eﬀect. Hence the values of the control experiments can be used to correct the batch eﬀect
in all the arrays.
The script uses the information from the TG-GATEs [47] described in section 3.2.7. It
computes the average of each gene value of all the control arrays for a given batch i (mB).
This value is then subtracted from each corresponding gene in each array that belongs to
the batch i in order to set the zero level of each batch to the same level. As this method
shifts the zero level to zero, we also calculate a universal mean of each gene as a mean of
all the controls (mT ), and add this value correspondingly to each gene of all the arrays.
See the illustration in Fig. 3.4.
3.3.1.4 Custom CDF -ﬁles
As stated before, in Aﬀymetrix GeneChips a probe set contains 11-20 pairs of oligonu-
cleotides to represent one target gene or transcript. However these probes are based on
earlier genome annotations, which are signiﬁcantly diﬀerent from current knowledge due
to the tremendous progress in genome sequencing in recent years. This new information
of gene sequences, directions and alternative splicing causes several problems and aﬀects
the analysis results. [12]
To solve this problem, Dai et al [12] have developed a procedure for reorganizing the
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Table 3.3: The principle of the design matrix used to ﬁt linear models to data.
File Control Disease
Vehicle1.CEL 1 0
Vehicle2.CEL 1 0
Hypertrophy1.CEL 0 1
Hypertrophy2.CEL 0 1
Hypertrophy3.CEL 0 1
Vehicle3.CEL 1 0
GeneChip probes into probe sets. The procedure is described in [12], but in short it
performs sequence alignments of GeneChip probe sequences with the most recent genome
sequence of the species in question (using BLAST), and chooses only those probes to a
probe set which have only one perfect match to the genome sequence and certain cluster.
It is also required that each probeset contains at least three probes and that they are all
from the same strand and have same direction. This procedure alters the sizes of probe
sets from three to several dozens of probes. [12]
The re-organized probe sets can be included in the data analysis by using Chip De-
scription Files (CDF). A CDF -ﬁle describes the link between probes and probesets, and
identiﬁes PM and MM probes and control probes. A new CDF-ﬁle is usually gener-
ated few times a year, and they can be downloaded from the website of the Microar-
ray lab of Molecular and Behavioral Neuroscience Institute of University of Michigan:
(http://brainarray.mbni.med.umich.edu/brainarray/Database/CustomCDF/genomic _cu-
rated_CDF.asp). Use of these customized CDF-ﬁles can improve the analysis results by
more than 20% (20% improvement was gained with HG-U133A -chip). Custom CDF-ﬁles
can be used in Bioconductor according to this example:
data <- ReadAffy(cdfname= HS133A_HS_UG) [12]
Nowadays also Aﬀymetrix annotation system maps probe sets to the latest UniGene
(http://www.ncbi.nlm.nih.gov/unigene) build every couple of months. Nevertheless it does
not react to situations where some of the probes in a probe set are assigned to another
gene or to multiple genes. Also many of the UniGene clusters are represented by multiple
probe sets in GeneChips. The custom CDF-ﬁles correct these issues as well. [45]
In this project we used Version 14 (released April 2nd, 2011) ENSG -ﬁles for rat 230.2
Aﬀymetrix arrays. Genome wide annotation-ﬁle for rat (org.Rn.eg.db) from Bioconductor
was used [9].
3.3.2 Diﬀerentially Expressed Genes
To analyze diﬀerential expression, linear models and limma -package for R were used. For
this purpose, a design -matrix was build, showing which samples are controls (treated only
with the vehicles) and which have some histopathological ﬁnding ( i.e. disease). Table 3.3
demonstrates how the design matrix was organized. [24, 60]
After this, lmFit -function was used to ﬁt a linear model for every gene. Next, a
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contrast matrix was created from the design matrix using makeContrasts -function. Then
the coeﬃcients and standard errors were computed with contrasts.fit -function. Finally,
standard errors were moderated using empirical Bayes method and eBayes -function. [24,
60, 59]
With topTable -function genes can be organized based on their p-values. The diﬀer-
entially expressed genes were picked up from this list using cut-oﬀs for p-values and for
fold-changes. In MicroArray Quality Control (MAQC) project [56] they present a recom-
mendation, that for a gene to be considered as diﬀerentially expressed, the p-value should
be less or equal to 0.001 and the mean diﬀerence greater than or equal to twofold. These
values are good for smaller datasets, but to see enough diﬀerential expression in this large
dataset, a p-value cut-oﬀ of 0.05 and fold-change cut-oﬀ of 1.5 were used. [24, 60, 59]
3.3.3 GO Enrichment
After determining the the diﬀerentially expressed genes, an attempt was made to identify
whether these genes form some gene sets: that is, whether some gene set is under- or
overpresented in the data. For this purpose function called hyperGTest was used. To
perform this hypergeometric testing, a gene universe and a list of interesting genes are
needed. Gene Ontologies (GO) were used to determine the gene sets. [24]
First, a gene universe was deﬁned as all the possible unique genes that exist on the
rat 230.2 array. Ensembl gene identiﬁers from the custom CDF-ﬁle were used to create
the universe. The interesting genes were the previously determined diﬀerentially expressed
genes. In addition to these, the name of the annotation data package (org.Rn.eg.db),
the GO ontology of interest (BP, Biological Process), the p-value cut-oﬀ (0.05) and the
test direction (over for overpresented) were given as parameters to hyperGTest -function.
[24, 21]
The results of the analysis were saved in a html-ﬁle using htmlReport -function. This
allows closer examination of the GO term names via AmiGO -gene ontology webpage
[48, 8, 21], as the names of GO terms are printed as html links. [24]
3.3.4 PCA
The principal component analysis (PCA) was performed to visualize the separation of the
controls and the arrays with histopathological ﬁndings. PCA was performed separately to
each histopathological group versus the controls.
Function prcomp was used to compute the principal components. Only those 50 probes
showing lowest p-values were used in the analysis. Expression matrix of these 50 probes
was transposed so that the function understood the gene expression levels as features of
the sample objects. The code is presented in Appendix A, Chapter A.1.
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3.3.5 KNN
K-nearest neighbor (KNN) classiﬁcation by cross-validation was used to determine how
well each histopathological group can be separated: for each group, one sample at a time
were classiﬁed using rest of the samples (controls and other samples from that group) as
training examples. Three closest neighbors were used for classiﬁcation. For this purpose,
the gene expression values were ﬁrst standardized (as is recommended in [24], see Chapter
9, Supervised Machine Learning). Then the Euclidean distances are computed (using dist
function). After this, the diﬀerentially expressed genes were organized according to their
t-statistic, and 50 ﬁrst ones were used for the analysis. Finally, knn.cv function was used
to compute the classiﬁcation results.
These results were then compared to the real classes (that is, was the sample marked as
control or to have certain histopathological ﬁndings). Accuracy, precision, sensitivity and
speciﬁcity of each classiﬁcation test was computed. The code is presented in Appendix A,
Chapter A.2.
3.3.6 Ingenuity Pathway Analysis
After the genes were listed and organized using the limma -package as described in section
3.3.2, these gene lists were uploaded to Ingenuity. For this purpose, an excel sheet was
produced with three columns: gene ID annotations, log fold changes and adjusted p-values.
Suitable cut-oﬀs were chosen, usually 0.001 for p-value and 1.2 for the fold change (equals
to 0.26 for log fold change). Both up- and down-regulated genes were considered.
Core Analysis function analyzes the data in the context of biological processes, path-
ways and networks. Signiﬁcance of the diﬀerent groups is tested using Fishers' Exact test
p-value. Some (Core, Tox or Metabolomics) Comparison Analyses were also performed
compare diﬀerent groups or to compare it to data from some single samples treated with
certain drugs. Lots of data from TG-GATEs and some using new possible drug candidates
were uploaded to Ingenuity earlier.
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4. RESULTS
In this chapter, analysis results are presented and brieﬂy discussed. First, the lists of diﬀer-
entially expressed genes (DEG) and the enriched gene ontology (GO) categories amongst
them are presented. To examine these DEGs and GOs further, the gene lists were up-
loaded to Ingenuity: some results from Core and Comparison Analyses are presented here.
Next the PCA and KNN results of separation between the ﬁve histopathology groups from
healthy controls are discussed. Correlation to other phenotypical ﬁndings are presented.
Those samples without any reported histopathological ﬁndings are examined further, and
some dose and time response analyses using these samples are shown.
Finally, the data from the ﬁve groups is compared to two known drug molecules and two
possible drug candidates. Analysis results from similar comparison analysis using diﬀerent
dose levels is also shown. The gene expression data from each group is also compared to
known toxicity -related pathway. Compounds responsible for the histopathological ﬁndings
are also brieﬂy mentioned and discussed.
4.1 Diﬀerentially Expressed Genes and GOs (Biomarkers)
For each of the ﬁve histopathology groups, diﬀerentially expressed genes (see Table 4.1)
and enriched gene ontologies (GO) among these were listed. In Table A.5 (Appendix)
one can see as an example the most diﬀerently expressed genes from comparison between
cellular change -group and controls. Gene symbols and names are presented together with
log2 fold-changes and adjusted p-values. For example genes Cyp2f4 (cytochrome P450)
and Apex1 (APEX nuclease) are reported to be regulated by toxic compounds [72]. To
get a better idea of what the changes in expression of these genes mean, GO enrichment
was performed. The gene lists were also uploaded to Ingenuity IPA for pathway analysis
(Chapter 4.2).
In Table A.10 (Appendix) the 50 enriched up-regulated biological process GO -categories
with lowest p-values are presented. One can see that many GO terms implying exposure
to interesting substances are amongst the enriched categories, for example response to
drug, response to toxin, cellular response to chemical stimulus and response to stress.
Several terms seem to be related to lipid metabolism (for example lipid metabolic pro-
cess, fatty acid metabolic process and lipid biosynthetic process). Terms like response
to nutrient levels and response to nutrient might indicate the eﬀects of the new diet
including the corn oil used as the vehicle when giving the compound as oral dose. These
issues were examined further with Ingenuity Core Analysis and Comparison Analysis.
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Table 4.1: Number of the samples and diﬀerentially expressed genes (DEGs) in each
histopathology group (cut-oﬀs used: adjusted p-value < 0.001 and log fold-change 1.2).
Also the number of diﬀerent compounds causing certain histopathological ﬁnding and the
number of those compounds that cause this ﬁnding in more than ﬁve treated samples are
presented.
Histopathology group No. of samples No. of DEGs No. compounds
(all/in > 5 cases)
Hypertrophy 442 229 47/28
Necrosis 77 66 40/1
Cellular change 124 98 26/8
Cellular inﬁltration 344 197 52/23
Vacuolar degeneration 173 880 25/ 10
4.2 Core Analysis Results
Interesting genes from each group were uploaded to Ingenuity IPA, and Core Analysis was
performed. Some results of these analysis are presented in Table 4.2, and in Appendixes.
From each analysis, Top Bio Functions of Molecular and Cellular Functions, Canonical
Pathways, Upstream regulators, Tox Lists, Tox Functions for Hepatotoxicity and Networks
are presented in the tables. Some of these results are also visualized in Fig. 4.1.
In Top Bio Functions and Top Tox Functions, the number of genes or molecules is
presented in parenthesis. In Canonical Pathways and Top Tox Lists the ratio of molecules
in the pathway meeting the cutoﬀ -criteria and the total number of molecules that make up
that pathway is given. In Top Networks, a network score is presented in parenthesis: the
score represents the likelihood that the molecules that are part of the network are found by
random chance alone. Mathematically it is the negative exponent of right-tailed Fishers
exact test result: for example score of 3 means that there is a 1 in 1000 chance that the
molecule is found by chance. [64]
In Top Bio Functions (Molecular and Cellular Functions) three groups arise in all
the ﬁve cases: Lipid Metabolism, Molecular Transport and Small Molecule Biochemistry.
Lipid Metabolism is related to both steatosis and cholestasis (via cholesterol and bile acid
biosynthesis). Molecular transport means functions associated with intra- and extracellu-
lar movement of any kind of molecules, and it may reﬂect the increased expression and
movements caused by it. Small Molecule Biochemistry describes functions associated with
small molecules such as nitric oxide or indole: activity of these functions may reﬂect the
treatment with the drugs.
Same things are visible also in Canonical Pathways; fatty acid metabolism and glyc-
erolipid metabolism reﬂect steatosis, and pathways like Xenobiotic Metabolism Signaling
and Metabolism of Xenobiotics by Cytochrome P450 indicate the treatment with drugs.
Also LPS/IL-1 Mediated Inhibition of RXR Function and PXR/RXR Activation path-
ways are seen in many cases: these pathways are related to hepatic acute phase response
(APR), which can be caused by infection, inﬂammation or injury. Very similar lists are
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Table 4.2: Top biofunctions, canonical pathways, upstream regulators, tox lists and net-
works from Ingenuitys Core analysis of diﬀerentially expressed genes from those samples
with hypertrophy as histopathological ﬁnding. In Top Bio Functions and Top Tox Func-
tions, the number of genes or molecules are presented in the parenthesis. In Canonical
Pathways and Top Tox Lists the ratio molecules in that pathway that meet the cut-oﬀ
criteria and the total number of molecules that make up that pathway is given. In Top
Networks a network score representing the likelihood that the molecules are found by
change is shown.
Hypertrophy-group (229 diﬀerentially expressed genes)
Top Bio Function, Top canonical pathways
Molecular and Cellular
Functions
Lipid Metabolism (67) Metabolism of Xenobiotics by Cytochrome P450 (12/196)
Small Molecule Biochemistry (83) LPS/IL-1 Mediated Inhibition of RXR Function (17/236)
Molecular Transport (64) Xenobiotic Metabolism Signaling (18/295)
Drug Metabolism (28) Fatty Acid Metabolism (12/183)
Energy Production (23) Nitrogen Metabolism (7/119)
Top Upstream regulators Top Tox Lists
PPARA (Activated) Xenobiotic Metabolism Signaling (23/347)
ciproﬁbrate (Activated) LPS/IL-1 Mediated Inhibition of RXR Function (19/246)
POR NRF2-mediated Oxidative Stress Response (18/231)
pirinixic acid (Activated) Fatty Acid Metabolism (13/123)
ACOX1 (Inhibited) CAR/RXR Activation (7/29)
Top Tox Functions, Hepatotoxicity
Liver Steatosis (19)
Hepatocellular Carcinoma (21)
Liver Hyperplasia/Hyperproliferation (21)
Glutathione Depletion In Liver (5)
Liver Cholestasis (6)
Top Networks
Drug Metabolism, Glutathione Depletion In Liver, Carbohydrate Metabolism (47)
Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry (37)
Cellular Assembly and Organization, DNA Replic., Recomb. and Repair, Molecular Transport (33)
Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral Metabolism (32)
Ophthalmic Disease, Respiratory Disease, Hereditary Disorder (28)
found from the Top Tox Lists as well.
Steatosis and Cholestasis emergence also in Hepatotoxic Top Tox Functions. Hepato-
cellular Carcinoma, Liver Hyperplasia/Hyperproliferation and Glutathione Depletion are
also seen in many cases, which makes sense, even though one would have expected to see
highest activity of steatosis and cholestasis in vacuolar degeneration -group and hyperpla-
sia/proliferation in hypertrophy. It should also be considered that even in hypertrophy-
group the bar for hypertrophy Tox Function is not over the threshold line: this might
reﬂect the diﬀerences in determination of terms in TGP and in Ingenuity, but also the fact
that Ingenuity database is created by text-mining scientiﬁc papers and it includes all the
data available from diﬀerent organisms, organs and methods.
Top Networks seem to reﬂect the necrotic situation in cells with histopathological issues
(Cell Morphology, Organ Development, Cell Cycle, Cell Death, Cellular Assembly and
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Organization), steatosis (Lipid Metabolism), cholestasis (Endocrine System Development
and Function, Nutritional Disease) and oxidative stress (glutathione depletion). Of the
upstream regulators, PPARA (peroxisome proliferator-activated receptor alpha) and POR
(P450 (cytochrome) oxidoreductase) come up in most cases. Activity of both molecules is
known to correlate with steatosis.
Figure 4.1: Some results of the Comparison Analysis done using Ingenuity IPA. From top
to bottom: Top Bio Functions, Top Tox Functions and Canonical Pathways.
4.3 PCA Results
Principal component analysis was performed for each of the histopathological groups and
controls. In (a) in Fig. 4.2, one of these plots is presented: controls are plotted with green
and samples with a certain histopathological ﬁnding in blue. More ﬁgures for rest of the
groups can be found from the Appendixes. Some groups form tight clusters whereas others
are more spread.
To get some explanation to the deviation of the data points in PCA plots presented
above, points were visualized with diﬀerent colors according to the dose, exposure time
and degree of the pathological ﬁnding. Some examples of these plots are shown in Fig.
4.2, rest of them can be found from the Appendixes. From these plots one can see that
4. Results 39
in some cases the doses, exposure times and severities of the ﬁnding seem to explain the
deviation (see for example hypertrophy -group).
4.4 KNN Results
KNN cross-validation (k=3) results are presented in Table 4.3 and are used to understand
how well diﬀerent groups are separated. Precision, accuracy, sensitivity and speciﬁcity were
computed for each of these classiﬁcations: these results are presented in Table 4.4. The
results are in agreement with the PCA results: all the groups detect the controls as one
group nicely (good speciﬁcity), but in all groups some percentage of the diseased samples
are classiﬁed as controls (not that good sensitivity).
As can be seen from the PCA images (Fig. A.1), vacuolar degeneration is most easily
separated (86 % of the samples are correctly classiﬁed). Rest of the results show surprising
sensitivities when compared to PCA: one would expect perhaps a lower percent for cellular
change and hypertrophy (75 % and 82 %, respectively), and higher for necrosis, of which
only 39 % of the diseased samples were correctly classiﬁed.
Table 4.3: Results of KNN cross-validation analysis (k=3) for all the ﬁve groups. In each
case, the column on the left represents the real groups, while the rows are the classiﬁed
groups. For example for necrosis: all the controls were classiﬁed correctly, while 47 of
those samples with necrosis were classiﬁed as controls, and 30 samples with necrosis were
classiﬁed correctly. 50 most diﬀerentially expressed genes were used for the analysis.
control Necrosis
control 1392 0
Necrosis 47 30
control Vacuolar degeneration
control 1392 0
Vacuolar degeneration 24 149
control Hypertrophy
control 1392 0
Hypertrophy 78 364
control Cellular inﬁltration
control 1392 0
Cellular inﬁltration 157 187
control Cellular change
control 1392 0
Cellular change 31 93
KNN cross-validation was also performed for all the ﬁve groups and controls. For this
analysis, all the gene values were used. The results are shown in Table 4.5.
Again, controls are classiﬁed nicely as their own group, but there are altogether 595
samples (≈ 50%) that are misclassiﬁed as controls. The situation is worst with cellular
inﬁltration and necrosis -groups as expected. The results are generally worse than in
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(a) (b)
(c) (d)
(e) (f)
Figure 4.2: A PCA plot showing the separation between vacuolar degeneration and controls
(a), also with diﬀerent dose levels (b), exposure times (c) and severities of the ﬁndings (d)
presented with diﬀerent colors. Also diﬀerent doses in a single time point (14 days) is
shown (e as well as diﬀerent time points in one dose level (f).
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Table 4.4: Precision, accuracy, sensitivity and speciﬁcity of each group vs. controls cross-
validation test with KNN.
Group: Precision Accuracy Sensitivity Speciﬁcity
Hypertrophy 1,00 0,96 0,82 1,00
Necrosis 1,00 0,97 0,39 1,00
Cellular change 1,00 0,98 0,75 1,00
Cellular inﬁltration 1,00 0,91 0,54 1,00
Vacuolar degeneration 1,00 0,98 0,86 1,00
case-wise comparison (Table 4.3), which is expected due to use of several groups and use
of all the gene expression values instead of just the 50 most diﬀerentially expressed.
Table 4.5 can be used to study the similarities between the histopathology groups. For
example, hypertrophy and cellular inﬁltration -groups seem to be similar at least to some
extend (about 5 % missclassiﬁcations).
Table 4.5: KNN cross-validation (k=3) results of all groups. Rows present the real classes
and columns the classes based on KNN.
Cellular Cellular Control Hypertrophy Necrosis Vacuolar
change inﬁltration degeneration
Cellular 51 7 58 3 1 4
change
Cellular 3 99 216 20 1 5
inﬁltration
Control 1 0 1391 0 0 0
Hypertrophy 1 18 219 201 1 2
Necrosis 3 2 56 1 10 5
Vacuolar 2 7 46 7 0 111
degeneration
4.5 Deviation of the Gene Expression Values
To visualize and study the actual diﬀerence in the deviation of the gene expression values
between controls and the histopathological groups, boxplots were generated. The highest
possible deviation in normal situation was also studied. The batch corrected and linearized
data of the most diﬀerentially expressed genes were used for these plots. For the example
plots presented in Fig. 4.3, ten of the most diﬀerentially expressed genes are shown for
hypertrophy and necrosis -groups. Example boxplots for the rest of the histopathology
groups can be found in Appendices.
From Fig. 4.3 one can see that in case of hypertrophy (a) the deviation of the gene
expression values between controls and samples with hypertrophy ﬁndings diﬀers nicely
in all ten genes. The diﬀerence is greatest with Utg1a1 and Gstm4 genes, but even with
these genes some overlap is seen in the whiskers and some outliers exist. However, this
plot encourages the study of certain gene expression values as possible biomarkers.
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With necrosis the situation is diﬀerent, as can be seen from boxplot (b) in Fig. 4.3. The
boxes of controls and treated samples overlap in all the ten cases, and the mean values (50th
percentiles, the line in the middle of the box) are not very far from each other. Compared
to hypertrophy group, the boxes and whiskers are much wider in necrosis (compare for
example Gsta5 -gene shown in both plots). This reﬂects the variety of mechanisms causing
necrosis, and the result is in agreement with KNN and PCA -results.
These plots give an idea of the deviation of gene expression values in normal situation
as well: in (a) and (b) in Fig. 4.3 the gene expression values in controls vary only slightly,
even though there were as many as 1392 control samples. Higher deviation in the treated
samples is explained partly by the diﬀerent doses and exposure times. To see the highest
possible deviation of gene expression values in normal situation, those 10 genes with highest
variation in the controls were chosen and plotted (Fig. 4.4). These genes take care of
normal daily variation in cells, and due to their high variation they are seldom listed as
diﬀerentially expressed genes and could not be used as biomarkers.
4.6 Correlation Between Histopathological Findings and Other
Phenotypic Findings
In Figure 4.5 the correlations between the histopathological groups and some other phe-
notypical ﬁndings are shown. For comparison, controls are shown on the left in each plot.
Chosen phenotypical ﬁndings are: (from top to bottom, right column:) ALT, AST, ALP
and (from top to bottom, left column:) TBIL, LDH and weight loss per day (see Chapter
3.2.6 for more information about these blood biochemistry values).
Figure 4.5 shows that there is relatively little correlation between a certain histopatho-
logical ﬁnding and any of the other phenotypical ﬁndings. Controls seem to show quite
wide variation in all the ﬁndings. Perhaps these results point out that even though the
blood samples in human indicate liver damage quite well, in rats the situation is diﬀerent.
The only signs of correlation can be seen with weight loss: all control rats have gained
weight or their weight has remained the same, while in all histopathology groups some
samples have lost weight.
To take a closer look on the deviation of the biochemistry values and weight loss,
histograms were used to compare the values to controls. As an example the weight loss
histogram is shown in Fig. 4.6. It can be seen that the mean of the weight loss is slightly
shifted to right in most cases.
4.7 Treated Samples Showing No Phenotypical Findings
In the data there were large amount of samples treated with some compound but from
which no phenotypical ﬁndings were reported (3621 samples, see Table 3.2). Also their
spread compared to the controls was studied to see how much they resemble the controls.
In Fig. 4.7 the produced PCA plot can be seen on the left. Clearly most of the samples
are very close to the controls, which is expected as they might be treated for only three
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(a) (b)
Figure 4.3: Boxplots showing deviation of gene expression values of chosen genes in controls
(green) and samples (blue) belonging to hypertrophy (a) and necrosis (b) groups. (The
bottom and top of the box are the 25th and 75th percentile, the band near the middle of
the box is the 50th percentile, and the whiskers show the most extreme data points which
are no more than 1.5 times the interquartile range from the box. Data points beyond this
range (outliers) are marked with circles.
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Figure 4.4: Boxplots showing deviation of gene expression values of those genes with highest
variation in controls. (The bottom and top of the box are the 25th and 75th percentile,
the band near the middle of the box is the 50th percentile, and the whiskers show the most
extreme data points which are no more than 1.5 times the interquartile range from the
box. Data points beyond this range (outliers) are marked with circles.
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(a) (b)
Figure 4.5: Figures showing the correlation between histopathological ﬁnding and other
phenotypical ﬁndings. Each point presents one array/rat. Phenotypical ﬁndings are (from
top to bottom): (a) ALT, AST, ALP and (b) TBIL, LDH and weight loss per day. In each
plot, the histopathological groups are (from left to right): Hypertrophy, Cellular change,
Cellular inﬁltration, Necrosis, Vacuolar degeneration and controls.
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Figure 4.6: Weight loss of the rats with certain histopathological ﬁndings (black stripes)
compared to the controls (blue). Normal curves are also shown to ease the comparison.
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days with the lowest dose. On the other hand, some part of the samples seem to be getting
further away from the controls.
To get a better idea of the factors causing the separation, samples were studied by
separating dose levels and time points with diﬀerent colors, as can be seen in Fig. 4.7
(upper row). It is diﬃcult to say whether any correlation can be noticed, even when
looking at the diﬀerent time points in only a single (high) dose or diﬀerent doses in one
time point (14 days), see Fig. 4.7 (lower row). Analysis with other time points and dose
levels alone produced somewhat similar results. Thus it can be determined that the type
of the drug used has more eﬀect on the separation than the dosage or the exposure time
in general.
4.8 Dose Response
To validate the analysis and to see the eﬀect of diﬀerent doses to the gene expression,
samples were organized as follows: ﬁrst only those samples causing certain histopathological
ﬁndings in more than ﬁve cases per compound when treated with highest dose were chosen.
After this, samples treated with corresponding compounds and middle or low dose but
which do not show any histopathological changes were chosen as their own groups. These
three groups (high, middle and low) were analyzed against controls, and the computed
p-values and (log) fold-changes were entered to Ingenuity. In Ingenuity IPA, a Comparison
Analysis was performed between these groups.
In Fig. 4.8 one can see as an example the dose response comparison analysis of those
samples causing vacuolar degeneration in the highest dose. Selected hepatotoxic functions
are shown. The most obvious dose response behavior is seen in steatosis: highest dose shows
lowest p-value (highest bar). This kind of behavior was expected, as those samples with
fatty degeneration (which can be considered as a synonym for steatosis) were included in
this histopathological group. Similar increasing trend can be seen in cholestasis, although
the values are closer to the threshold.
On the other hand, the trend seems to be reversed with inﬂammation, glutathione
depletion and damage. This seems controversial, as it would be expected to see more
damage, oxidative stress and inﬂammation with higher doses (that is, to see more activation
in genes responsible for these situations). There are few possible reasons behind this
behavior. The dose might be that lethal to the cells that they are close to apoptosis
or necrosis, and thus will not react to these situations. Expression of genes related to
regeneration could give information about this situation, but in this case the p-values of
these genes were under the threshold limit.
Another option is that cells or the whole organ may have adapted to the situation as
well, and the change can hence be visualized in some other genes. Third and perhaps
the most likely explanation would be that the levels of the proteins needed are already
as high as possible or high enough considering the situation. Therefore the expression
can return to normal level as new proteins are needed only to supplement the decayed
ones. This situation reﬂects the challenges of toxicogenomics: gene expression values can
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(a) (b)
(c) (d)
(e)
Figure 4.7: PCA plots showing (a) the separation between treated samples without any
histopathological ﬁndings (blue or coloured) and controls (green or black), also with dif-
ferent dose levels (b) and exposure times (c) presented with diﬀerent colors. Also those
samples with 14 days exposure time (d) and those samples treated with the highest dose
(e) are shown.
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be somewhat miss-leading if one does not have any references or enough data.
Figure 4.8: An example showing dose correlation (analysis done in Ingenuity IPA). Those
samples showing vacuolar degeneration when treated with highest dose (lightest blue, bar
on right) compared to those samples treated with same compounds (expected to cause
vacuolar degeneration with higher doses or longer time) treated with middle and low dose
(sky blue, in the middle and the darkest blue, on left). Notice that the scale in y-axis is
−log10(p− value): the light orange threshold line is drawn at p-value = 0.05.
4.9 Time Response
Similarly to the dose response analysis described above, time response analysis with two
time points (early = 3 and 7 days, late = 14 and 28 days) was prepared. Only the
highest dose level was used, and the samples in late time point were required to show
histopathological changes while the samples in the early time point were required to be
clean. There was reasonable amount of data (i.e. enough samples) only in one group,
hypertrophy.
Comparison Analysis was performed in Ingenuity IPA similarly as with dose response.
The four time points of samples treated with aspirin were plotted in the same image for
comparison. In Fig. 4.9 one can see some of the results (chosen Top Tox Functions).
Based solely on the two time points, it is diﬃcult to say whether time response is
actually seen or not. Nevertheless, compared to the dose response results, same kind of
behavior is noticed in the same groups (for example steatosis is incresing as the dose or
the exposure time is increased). However, the aspirin data seems to follow this assumed
time behavior poorly: one must keep in mind that there are only three samples in each
aspirin -group and thus more variation.
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Figure 4.9: Comparison Analysis of two time points, early (3 and 7 days of treatment)
and late (14 and 28 days) of samples showing hypertrophy in the later time point but not
in the earlier. For comparison, all four time points treated with aspirin are also shown.
Analysis done with Ingenuity IPA.
4.10 Use of the Data in Drug Development: Comparison to
Few Examples
To see whether the data from the histopathology groups can be used to analyze the toxicity
of possible drug candidates, a comparison analysis was performed in Ingenuity IPA using
all of the ﬁve histopathology groups, two well-known drugs (ibuprofen and aspirin) and
two drug candidates (referred here as molecules A and B). Some of the results from this
analysis can be seen in Fig. 4.10.
Data of samples treated with ibuprofen and aspirin are from TG-GATEs. Data for
molecules A and B was produced similarly. In all four cases, highest dose and longest
available time-point was chosen in order to see maximal toxicity: for ibuprofen and aspirin
the exposure time was 28 days and the doses were 200 mg/kg and 450 mg/kg, respectively.
For molecules A and B the treatment time was 14 days and the doses were 600 mg/kg
and 2000 mg/kg. One must keep in mind that these doses are ten times higher than the
intended pharmacological dose for humans.
This data shows that the highest doses of even the well-known drugs can cause serious
hepatotoxicity and damage to liver. Especially gene expression changes indicating steatosis
is seen in all the four example samples treated with drug molecules. However, as we
learned from the dose-response behavior in Chapter 4.8, this kind of presentation might
be misleading, as we do not know whether some of the cases have gone past of a certain
stage. For example, it might be that the four drug molecule samples have already reached
the maximum levels of those proteins that take care of glutathione depletion, and thus the
bars are seen lower. On the other hand the situation might as well be that the cells in
those samples are not suﬀering from oxidative stress, and therefore the corresponding gene
expression levels are maintained relatively low. Hence the next step is to compare dose
responses of the diﬀerent groups and to see whether they show similar trends.
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Figure 4.10: Here the data from diﬀerent histopathology groups is compared to two well-
known drugs (ibuprofen and aspirin) and two drug candidate molecules (referred here as
molecule A and molecule B). Similarly to Fig. 4.8 some of the most interesting toxicity
functions are shown. The scale in y-axis is −log10(p − value): the light orange threshold
line is drawn at p-value = 0.05. Image produced with Ingenuity and modiﬁed.
In Fig. 4.11, samples showing vacuolar degeneration in histopathology and treated with
the three diﬀerent dose levels (low, middle, high, corresponding to 1, 3 and 10 times the
medical dose) are compared to data from samples treated with ibuprofen in similar doses
(20 mg/kg, 60 mg/kg and 200 mg/kg). (Note: ibuprofen was reported to cause only slight
(4 samples) or moderate (2 samples) increased mitosis in TG-GATEs.) Similar trends were
noticed, and this data conﬁrms that ibuprofen is likely to cause steatosis and cholestasis
in higher dose levels, as was ﬁrst speculated based on the previous results (Fig. 4.10).
On the other hand, it seems that the case might be diﬀerent with glutathione deple-
tion: whereas in the samples treated with compounds causing vacuolar degeneration seem
to defend against oxidative stress even with the lowest dose and not as much with the
higher doses, the samples treated with ibuprofen seem to show increase in expression of
corresponding genes only with the highest dose. The situation seems to be similar also
with genes indicating liver damage, which would support this theory. This case is however
more ambiguous as the p-values are closer to the threshold.
4.11 Comparison to Other Results
Same in vivo liver -data from TG-GATEs was used in a publication by Low et al ([39]),
where they studied classiﬁcation and prediction of hepatotoxicity using toxicogenomics
and chemical features. They classiﬁed the data of 127 compounds in the database as
hepatotoxic or nonhepatotoxic based on the histopathological ﬁndings and in some cases
based on serum chemistry. They found 53 hepatotoxic compounds and 74 nonhepatotoxic
ones. [39]
Based on the gene expression analysis performed to these groups, they discovered three
pathways leading to long-term toxicity: these are Hnf4α-, Myc- and Eif2-centered networks.
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Figure 4.11: Comparison between one of the histopathology groups, vacuolar degeneration,
and an example drug, ibuprofen, with the three dose levels. Ibuprofen samples were treated
for 28 days. The scale in y-axis is −log10(p − value): the light orange threshold line is
drawn at p-value = 0.05. Image produced with Ingenuity and modiﬁed.
Hnf4α is a transcriptional factor that functions in morphological and functional diﬀeren-
tiation of hepatocytes, cell proliferation and detoxiﬁcation, and it also has a function in
the response to endoplasmic reticulum (ER) stress, which is caused by many toxicants.
Also Eif2 signaling pathway seems to be central in liver damage through ER stress. Myc
is transcriptional factor regulating cell proliferation, diﬀerentiation and apoptosis. In the
study by Low et al [39] they show that both Hnf4α and Myc -centered pathways contain
several up-regulated genes, which indicates that liver cells are feeling damage causing stress
(see Fig. A.5 B borrowed from the publication in Appendixes). [39]
To compare our analysis with these results and to see whether some of the histopatholog-
ical groups show particular up-regulation in the Myc-centered network, exactly the same
network was build using Ingenuity IPA. After this, the data from the analysis of each
histopathological group was overlayed on the network. Results and the original network
from the study by Low et al [39] can be seen in the Appendixes, Fig. A.5.
Altogether the networks of the ﬁve histopathology groups show rather similar behavior,
and many molecules in the Myc-network are, as expected, up-regulated. These include
for example nucleophosmin 1 (Npm1) and TATA box binding protein -associated factor
(Taf9), which are mentioned in the publication [39]. However, the general transcription
factor IIIC polypeptide 3 (Gtf3c3), which was (according to the publication) expected
to be up-regulated, showed no signs of speciﬁc regulation. Some components show also
unexpected down-regulation, for example glucocorticoid nuclear receptor Nr3c1, which
shows clear down-regulation in all groups. As the activation of Myc-centered network
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indicates long-term toxicity and general stress, it was expected to see very little variation
between the diﬀerent hepatotoxic groups.
This comparison shows that this kind of networks indicating general hepatotoxicity
can be used to support the classiﬁcation between hepatotoxic and non-hepatotoxic, but
regulation of single transcription factors (like Gtf3c3 or Nr3c1) can be misleading. Same
kind of analysis was also performed for some samples treated with drugs that were known
to be toxic in high doses (for example aspirin and WY-14643, which were classiﬁed toxic
by Low et al [39]), and in some cases only some activation was noticed (aspirin), but some
cases show high regulation even in the lowest doses and shortest exposures (WY-14643).
4.12 Compounds Responsible for Histopathological Findings
For the analysis purposes the compounds causing each histopathological ﬁnding were also
studied (Fig. 4.12). It was noticed that some of the ﬁndings are caused by many diﬀerent
compounds (hypertrophy, cellular inﬁltration) while others are caused only by few (cellular
change, vacuolar degeneration). In all groups some noise was noticed: there are several
compounds noticed to cause one type of phenotype in only one or two samples. There were
also several controls (tens in each case) with histopathological ﬁndings reported: these were
excluded from the analysis.
These samples reﬂect the individual diﬀerences between the test organisms, and even
though they may contain valuable information about diﬀerent responses to the compounds,
they might be problematic in analysis of the histopathology groups. As all the available
data treated with a compound and reported to have histopathological ﬁndings in liver were
used in the analysis, these noise samples are likely to cause variation in the results. This
can be seen for example in PCA plots.
Some compounds stand out in more than one group (for example simvastatin, diaze-
bam). In fact most of the samples reported to contain some phenotypical changes had
several diﬀerent histopathological ﬁndings: here only the most severe (or, in case of a tie,
the ﬁrst in alphabetical order) was chosen as the phenotype. This partly explains the
similarity between the groups, but as can be seen from the Comparison Analyses (Chapter
4.2), the grouping used here also manages to emphasize the diﬀerences between the groups.
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Figure 4.12: Diﬀerent compounds causing certain histopathological ﬁndings when treated
with any dose (low, middle or high).
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5. DISCUSSION
In this chapter the results are brieﬂy discussed and some conclusions are drawn based
on them. Possible use of the knowledge gained in this study are speculated. Problems
observed while analyzing the results are discussed, as well as possible future directions.
5.1 Summaries of the Results
Based on the PCA and KNN results (see Chapters 4.3 and 4.4) it was noticed that while
some histopathology groups are very clearly separated from the controls (for example
hypertrophy and vacuolar degeneration), others seem to be nearly impossible to detect
(for example necrosis and cellular inﬁltration). One likely explanation for poor separation
is that both with necrosis and cellular inﬁltration mostly minimal ﬁndings were reported
(see Fig. A.4), and thus those samples were closer to controls. The deviation in necrosis-
group is also explained by the fact that necrosis is caused by several diﬀerent drugs with
diﬀerent mechanisms.
Another probable reason for poor separation and wide spread between samples with
cellular inﬁltration and the controls is that the deﬁnition of the group is quite wide: it
contains all reported cellular inﬁltrations, ground glass appearances and microgranulomas.
The explanation might also be partly biological: gene expression might have a larger role in
some of the histopathologies, whereas others might be visible in other regulatory systems.
This is supported by the fact that the number of diﬀerently expressed genes does not
correlate with the amount of data (number of samples) in that group.
Based on Fig. 4.12, the amount of diﬀerent compounds causing the certain phenotype
does not seem to correlate with the spread of the samples in PCA images: for example
hypertrophy is caused by 47 diﬀerent compounds, but the group is still very tight in the
PCA image. This might indicate that the mechanisms causing hypertrophy are quite
similar regardless of the compound causing it.
Even though vacuolar degeneration was as a group nicely separated from the controls
(88 % sensitivity), PCA image seems to show several smaller clusters within the group.
One explanation is the diﬀerent, more detailed ﬁndings grouped together (see 5.1): clearly
part of the samples reported to have eosinophilic granular degeneration seems to form a
cluster of their own. This indicates that there might be two diﬀerent mechanisms causing
this ﬁnding.
Each of the ﬁve histopathological groups were studied by listing the diﬀerentially ex-
pressed genes and enriched GO gategories, and by performing Core and Comparison Anal-
yses with Ingenuity IPA. The analysis done using Ingenuity IPA (see Fig. 4.1 and Core
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Figure 5.1: PCA image showing the more precise histopathological terms in vacuolar degen-
eration -group. (Deg. is short for degeneration, gran = granular, eosinoph. = eosinophilic,
cytopl. = cytoplasmic and vacuol. = vacuolization/vacuolation)
Analysis -tables in Appendixes) reveals that especially the groups vacuolar degeneration,
hypertrophy and cellular change seem to activate pathways related to steatosis. Besides
this, cellular change -group seems to activate cholestasis, and hypertrophy -group glu-
tathione depletion related pathways. These results are as expected. None of the group
seem to highly activate liver damage or cell death -related pathways, which is assumed to
be due to the long lasted situation: these genes have reached their expression peaks earlier.
Markers of general toxicity were also studied: gene expression of each of the ﬁve groups
were overlayed on a Myc-centered pathway, which is assumed to be related to toxicity. It
seems based on the result images (see Fig. A.5) that each group activates this pathway.
This supports the use of this kind of indicator pathways for general toxicity.
No clear correlation between diﬀerent histopathological ﬁndings and blood biochemistry
values nor weight-loss of the rats were noticed. In human these blood values usually reﬂect
some events taking place in the liver, but the case might be diﬀerent with rats.
It was also noticed that the deviation of the gene expression values varies between
genes. In some genes the expression values from 1392 control samples were really close
to each other, whereas with other genes the spread was very large. Those samples with
less variation in the controls are more likely to function as possible biomarkers. This kind
of upper and lower limit -analysis would ease the estimation of severities of abnormal
situations in the samples.
Based on the dose response analysis (see Chapter 4.8) performed to vacuolar degenera-
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tion -group it can be concluded that in most cases the dose behavior seems evident. As it
was possible to analyze time behavior with only two time points and using only one of the
groups (Chapter 4.9), it is challenging to conclude whether some response is actually seen
or not. Some dose and time behavior is also visible in the PCA images (Fig. A.2 and Fig.
A.3), especially with hypertrophy -samples. As both dose and time response comparisons
contained data with no phenotypical ﬁndings as the lower doses or earlier timepoint, these
results encourage to use gene expression activity of certain pathways or gene groups as
possible early biomerkers.
Some comparisons of certain well-known drugs and some possible drug candidates were
performed against the ﬁve data groups. In Fig. 4.10 one can see that the data can be used
as a benchmark when estimating possible hepatotoxicity of new (or old) drug molecules.
As the data is quite large, the results can be considered quite reliable.
5.2 Relevance of the Results
As mentioned in Chapter 5.1, the analyzed data of the ﬁve histopathology groups can
be used as benchmarks for the amount of changes in gene expression. By comparing
new, similarly produced and analyzed microarray data to gene expression values of certain
pathways and groups (for example those highlighted in this report), some conclusions can
be drawn about possible hepatotoxicity of these compounds.
Especially the dose and time response data provide nice opportunities for comparison
analyses. Based on these analyses, it seems that it might be possible to see some indicators
of developing histopathological ﬁndings before they are seen in the phenotype (predictive
use). Some time points or dose levels are needed from the new analyses as well to see the
development of the situation: from single snapshots it is impossible to say whether the
gene expression is at its highest peak, already sinking or just random ﬂuctuation. Thus
use of only toxicogenomics in decision making might be diﬃcult and erroneous.
Ingenuity and GO enrichment analysis allows one to study the mechanisms of diﬀerent
hepatotoxicities in gene level. This could be useful when developing and modifying the
drug to a less toxic direction.
Usually gene expression studies are challenged by the dimensions of the data: samples
treated in certain way are compared to controls. The knowledge about the actual situa-
tion in the treated sample (its phenotype) might be very insuﬃcient. Here we know the
phenotype, and the transcript proﬁles could be explained based on this. This and the fact
that the data is relatively large and the analyses are performed systematically (same arrays
and protocols used etc.) makes these ﬁve groups a strong baseline to any hepatotoxicity
analysis.
When performing the Ingenuity IPA analyses, it was noted that the results were in some
cases slightly unexpected: for example, it had been expected to see higher activation in
genes related to hypertrophy in hypertrophy-group. This situation might reﬂect the diﬀer-
ence between a speciﬁc microarray study (using in vivo rats liver samples) and text-mining
approach used when creating the Ingenuity-database. For example Ingenuity includes in
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the analyses all available data from diﬀerent organisms (human, rat, mouse etc.), diﬀerent
organs (liver, kidney, brain etc.) and diﬀerent kind of studies (in vivo, in vitro). Thus
the results must be used only as directional and the information about the treatment and
phenotype of the sample are needed in the analysis. This also points out that it is wise to
use several tools and databases instead of only trusting one.
5.3 Other Observations
Besides the results reported in Chapter 4, many general observations were made during
the data analysis process. Here the complexity of genomics, use of rat as the main model
organism in drug development are discussed. Some concerns and error sources are also
presented, as well as future perspectives and other possible techniques.
5.3.1 Complexity of Genomics
Molecular networks and molecular/protein/gene interactions increase the complexity of the
gene expression process, which adds challenges to toxicogenomics. By analyzing mRNA
levels we get information of which genes are up- or downregulated, but we do not know
which mRNAs are ﬁnally translated into proteins, how fast this happens, how many pro-
teins are produced from one mRNA, how soon the mRNA is degraded, how much of a
certain protein is needed to make a notable change to the situation in the cell and so on.
Some regulation happens only on the protein level. Due to the networks, pathways and
compensatory eﬀects the direction of the regulation might not be that informative either.
Besides this, one must remember that the mRNA is gathered from a sample that contains
multiple cells: the values are averages over diﬀerent cells at slightly diﬀerent environments
and situations, and perhaps of diﬀerent cell types as well.
Thus, instead of actual values (compared to for example hemoglobin value in blood,
with know boundaries and understandable unit), we get probabilities that something has
happened. By taking advantage of the biological knowledge gathered in databases about
networks, pathways and molecule interactions and their relations to diﬀerent situations
(diseases and symptoms), we can relate these single probabilities into larger entities and
ﬁgure out what has happened.
5.3.2 Rat as Model Organism
In the data, tens of samples treated with vehicles only (the controls) were reported to have
some histopathological ﬁndings in liver. These samples were excluded from the analysis,
but they do reﬂect the eﬀect of the vehicle diet [65] as well as the diﬀerences between
individual rats: some rats are more sensitive to develop abnormalities than others, even
though the experimental arrangement is such that each rat should be treated similarly.
Diﬀerences in genetics caused by the environment (epigenetics) and other individual diﬀer-
ences caused by the environment and history are still visible. These diﬀerences are likely
to be in much higher level between individual humans, which makes it more diﬃcult to
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predict whether the drug will cause toxic responses in some individuals. [53]
Rat has been used as a model organism in drug development for a long time. Reasons
for this are the fast breeding and relatively easy handling, but also the durability of the
rat: it will stand really high doses of toxic compounds. Toxicogenomics uses overly high
doses in order to force the toxic eﬀects, and therefore the animal has to tolerate them,
but does this skew the results?
It could be that nothing implying toxicity is found from the rats, but in other test
animals even the low doses cause symptoms: drug development is often criticized for
developing drugs for rats. Due to its several good qualities as test organism and since
regulations (by FDA) require certain toxicity tests done with rats, it is likely to be used
as the main non-clinical test animal in future as well. For this purpose, it would be really
useful to study the possibilities to link toxicogenomic results from rats with other organisms
as well.
TG-GATEs has made an eﬀort towards this direction, as similar information is gathered
from rat in vivo and in vitro tests and from human cell in vitro tests. Some early results
from ﬁrst attempts to bridge between in vivo and in vitro and between rat and human are
reported in [67]. For example expression changes in genes related to cell proliferation and
apoptosis were detected in vivo but not in vitro. Between rats and humans, the patterns of
changes were similar, but the extent of the changes was greater in rat cells than in human
cells.
5.3.3 Possible Sources of Errors and Other Concerns
Besides the aforementioned individual diﬀerences between the rats and their special dura-
bility, one should keep in mind that the grouping used in this project was based on visual
inspection of the histopathological samples: two histopathologists examined the liver sam-
ples with a microscope and graded the ﬁndings according to certain instructions. Even
though this was done systematically and in blinded manner, the eﬀect of chance (for exam-
ple from which part the sample was taken, which areas were analyzed with the microscope)
and possible lack of repeatability (due to individual opinions) can not be ignored.
Some universal standards for the histopathology and other terms could maybe improve
these studies as well. Especially with histopathology terms some universal scoring system
would also be helpful. Besides this, samples were chosen to belong to only one group even
if several diﬀerent ﬁndings were reported. However, based on the results it seems that the
used grouping managed to highlight the diﬀerences between the groups.
5.4 Further Analyses and Future Perspectives
Next step in the analysis would be to further validate the use of the data as benchmark by
testing the classiﬁcation with an new sample with known histopathological ﬁndings. PCA,
KNN classiﬁcation and hierarchical clustering would show how this new sample settles
in the data. By comparing the gene expression values of the new sample to the gene
expression deviations of the controls and diﬀerent groups would be interesting as well.
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The new data should preferably be from a similar experiment, i.e. using Aﬀymetrix
Genechip (Rat Genome 230 2.0 Array) and rat liver in vivo -samples treated with some
compound for 3-28 days. Controls and batch correction for this new data are also needed.
It might be diﬃcult to ﬁnd data that ﬁts in to this description, and thus some bridging
between diﬀerent microarrays and experiments would be really useful as well, especially as
the techniques are constantly developing.
As stated before, the histopathology groups used in this study were quite broad: use
of smaller groups (sub-groups) might bring more insight to the analysis. Another option
would be to try to combine those drugs with similar mechanisms, target molecules or
structure and analyze them as a group.
It would be interesting also to choose some of the diﬀerentially expressed genes and test
their use as biomarkers. These genes could be chosen based on the gene expression value
deviation plots shown in section 4.5 or based on the analyses performed with Ingenuity.
Their reliability could be tested by using them in the classiﬁcation and clustering. They
could also be studied further using diﬀerent databases and text-mining approach.
As stated before, some bridging is needed between the in vivo and in vitro experiments
and between rat and human samples. TG-GATEs database is aiming towards this direction
[67]: as there already is some rat and human in vitro data available from experiments
performed with the same compounds and techniques, it would be interesting to compare
them to the data used in this project.
One of the goals in toxicogenomics is to enable toxicity analyses with lower doses and
shorter exposure times. This way smaller amount of the possible drug candidate would
be suﬃcient, and time could be saved in synthesis as well as with the experiments. The
results showed that based on the transcript proﬁles it might be possible to predict hepa-
totoxicity before it is seen in the phenotype. FDA and MAQC seem to support this kind
of development.
Predictive use in toxicogenomics is not the only use of genomics in drug development.
As stated before, transcript proﬁling can also be used to study the mechanisms of toxicity
and function of the drug candidate. With help of this information, the drug molecule could
be improved. Genomics could also be used in attempts to personalize medicine: certain
single-nucleotide polymorphisms (SNPs) are known to be associated with certain kind of
drug responses. [42, 53]
As stated by D.L.Mendrick in [43], biomarkers of toxicity are needed to both A) provide
additional tools for the clinical management of patients and to enable preventive measures,
and B) identify unsafe drugs earlier in development and predict the possible toxicity in
many patients or certain individuals. However, tissue samples are rarely available, and
hence it would be really useful to search biomarkers from blood samples. [43]
Even though peripheral blood cells can be used to study tissue damage or dysfunc-
tion due to diseases, there is rather little evidence of this kind of detection of toxicity.
One example is the prediction of exposure to harmful levels of acetoaminophen from the
expression signatures in rat [7]: these rat genes were translated to corresponding human
genes (=orthologs) and successfully used to classify acetaminophen-toxicated patients from
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controls. This is a very encouraging result suggesting that it would be wise to study the
blood cell samples as well. [43]
5.4.1 Other Techniques
As discussed before, toxicogenomics and microarrays are mainly qualitative methods, and
although they are widely used in diﬀerent ﬁelds including toxicogenomics, their use has
certain challenges. Several other methods that could be used in similar studies exist and
some of them are presented here. In order to achieve conﬁdent research results, combina-
tions of these methods should be used. These combinations and comparisons could also
bring light to the knowledge of both techniques.
Proteomics, i.e. the high throughput separation, display and identiﬁcation of pro-
teins, might prove as a at least equally useful technique for drug development as genomics
which is based on transcripts, and it might not indicate much about the actual protein
levels. Proteomics includes techniques from gel electrophoresis to mass spectrometry. The
advantage of proteomics is that body ﬂuids can be studied without need for cellular ma-
terial, and since many proteins are secreted to the ﬂuids, it could be possible to predict
physiological states based on their amounts. [34]
Same advantages concern metabolomics. Metabolomics measures all or a subset of
concentrations of small molecular weight metabolites in a certain system (for example
body ﬂuid) [33]. Usually a separation step such as chromatography or electrophoresis is
performed ﬁrst and then a identiﬁcation step like mass spectrometry follows [33]. Especially
with clinical environment protein or metabolite biomarker would be better, as they could
be tested with immonoassays which are generally faster than genomic/genetic tests. On
the other hand metabolomics is more sensitive to unwanted variation caused by diﬀerent
diets than gemomics. [43]
Genomics is a qualitative method: based on the results it can be said that something
happened, but it is more diﬃcult to say how serious the event was. Quantitative reverse
transcriptase polymerase chain reaction (QC RT-PCR) would give a sense of magni-
tudes of the changes. In QR RT-PCR the mRNA samples are reversibly transcriped to
DNA, which is then ampliﬁed. Using internal reference genes the exact amount of mRNA
molecules can be determined. [23]
Transcriptome is the complete set of transcripts (including mRNAs, non-coding RNAs
and small RNAs) in a cell and their quantities. To analyze the transcriptome, a method
called RNA-Seq can be used. It is often referred to as next generation sequencing method.
In RNA-Seq, a population of (fractioned) RNA is converted to a library of cDNA fragments
with adaptors attached to one or both ends. Each molecule is then sequenced in a high-
throughput manner to obtain short sequences from one end (single-end sequencing) or both
ends (pair-end sequencing). After this the resulting reads are either aligned to reference
transcripts, or a new genome scale transcription map is assembled de novo. [71, 44]
RNA-Seq is still under development, although several commercial systems have been
published (Illumina, Applied Biosystems SOLiD, Roche 454 Life Science). It is likely to
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be the next highly used technology in the ﬁeld due to its many beneﬁts: it is not limited
by existing genomic sequences, it has very low background signal and high dynamic range
(even greater than 9,000-fold range, compared to maximum of few-hundredfold range in
microarrays) and it is highly accurate for quantifying expression levels. Challenges are
related to bias caused by fragmenting, and to analysis and complexity of the data. [71]
63
6. CONCLUSIONS
The aim of this project was to study whether it is possible to recognize typical gene
expression proﬁles for certain phenotypical (i.e. histopathological) changes in liver samples.
Another goal was to study whether this data can be used as a reference when predicting
possible histopathologies in future samples treated with possible drug candidates, and thus
to aid in the search of suitable biomarkers of toxicity. These biomarkers would support early
stage drug development. For this purpose, data from in vivo gene expression studies of rat
liver from Japanese Toxicogenomics Project database (TG-GATEs) was used. Possibility
of using smaller doses and shorter experiment times in order to save resources was studied
by comparing diﬀerent exposure times and dose levels.
Identiﬁcation of histopathology groups was studied with PCA, KNN cross-validation
and comparison of diﬀerentially expressed genes and enriched gene ontology classes and
pathways. Some histopathology groups showed good separation from other groups and con-
trols, whereas others were more spread. Spreading was likely to be caused by experimental
factors, such as diﬀerent dose levels, exposure times, severities of the ﬁndings and by the
looseness in the deﬁnition of the group, but also diﬀerent mechanisms causing a certain
type of histopathology. As expected, genes in pathways related to steatosis, cholestasis and
glutathione depletion were diﬀerentially expressed in most of the groups. Also pathways
known to indicate toxicity (such as Myc-centered pathway) were activated.
From the comparisons between the histopathology groups and drug molecules (both
well-known and possible drug candidates) it was noticed that the data can be used as a
benchmark describing the levels of gene expression in hepatotoxicity. Similarly the devi-
ation of the gene values in control group and in the histopathology groups can be used
as a measure of changes in gene expression. The extend and systematic protocol of the
TG-GATEs makes this data a strong baseline to analysis.
Treated samples without any histopathological ﬁndings were used in dose and time
response analysis and some responsive behavior was noticed. This encourages the use of
gene expression proﬁles as early biomarkers, as predictive changes were noticed in gene
expression before anything was noticed in phenotype. However these studies also suggest
that few time and dose points are needed in future analyses as well, as the direction of the
changes is diﬃcult to see from single snapshots of gene expression. No correlation between
histopathological ﬁndings and blood biochemistry values were noticed, which reﬂects the
diﬀerence between rat and human. Some correlation to weight-loss was noticed, which
proves that the compounds were indeed harmful for the test animals.
When considering the results one should keep in mind that the samples may have
contained diﬀerent kinds of liver cells, and that the determination of the histopathological
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groups was based on individual visual inspection. It is also advisable to keep in mind the
complexity of gene expression and thus not rely heavily on single gene values or directions of
the regulation, but rather to examine overall pictures gained by gene ontology enrichments
or pathway analyses. The data can be used in estimation of toxicity as one measure
amongst others and as a benchmark: it is relatively easy to compare future analysis results
to the data using Ingenuity IPA. The results can also be used when studying mechanisms
of toxicity, and hence possibly to guide the direction of development of a candidate drug
molecule.
In the future, it would be interesting to study in a similar way the bridging between this
in vivo data and corresponding in vitro data from TG-GATEs. Then also the diﬀerences
and similarities between rat and human samples could be studied. Other histopathological
groups could be studied as well, and the groups could be determined more speciﬁcally in
order to get more precise information about each case. The use of the data as benchmark
could also be further validated and tested by using it in classiﬁcation of new samples with
known histopathological ﬁndings. Some of the diﬀerentially expressed genes found in this
project and the possibility of using them as biomarkers of hepatotoxicity could also be
further studied. It might also be interesting to see the correlation of the ﬁndings presented
here to gene expression measured from blood samples, as some encouraging results of this
kind of studies exist.
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A. APPENDIXES
A.1 PCA code
# Order according to the t-statistic:
rtt = rowttests(Dataset, factor(Dataset$state))
ordtt <- order(rtt$p.value)
esTT = Dataset[ordtt[1:50],]
# Perform PCA and plot the results:
pc = prcomp(t(exprs(esTT)))
plot(pc$x)
A.2 KNN code
# Standardize the gene expression values:
rowIQRs = function(eSet) {
numSamp = ncol(eSet)
lowQ = row(eSet, floor(0.25 *numSamp))
upQ = row(eSet, ceiling(0.75 *numSamp))
upQ - lowQ
}
standardize = function(x) (x-rowMedians(x))/rowIQRs(x)
exprs(Dataset) = standardize(exprs(Dataset))
# To compute the distances:
eucD = dist(t(exprs(Dataset)))
eucM = as.matrix(eucD)
# To choose only 50 features:
Traintt = rowtttest(Dataset, ''state'')
ordTT = order(abs(Traintt$statistic), decreasing = TRUE)
Trainset = Trainset[ordTT[1:50]]
# Cross-validation:
train = t(exprs(Trainset))
cl = as.factor(Trainset$state)
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knn_results = knn.cv(train, cl)
# To compare the results to known classes:
knntable <- table(Trainset$state, knn_results)
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A.3 Tables and Figures
Table A.1: Top biofunctions, canonical pathways, upstream regulators, tox lists and net-
works from Ingenuitys Core analysis of diﬀerentially expressed genes from those samples
with necrosis as histopathological ﬁnding. In Top Bio Functions and Top Tox Functions,
the number of genes or molecules are presented in the parenthesis. In Canonical Pathways
and Top Tox Lists the ratio molecules in that pathway that meet the cut-oﬀ criteria and
the total number of molecules that make up that pathway is given. In Top Networks a
network score representing the likelihood that the molecules are found by change is shown.
Necrosis-group (66 diﬀerentially expressed genes)
Top Bio Function, Top Canonical Pathways
Molecular and Cellular
Functions
Cell Cycle (11) Aryl Hydrocarbon Receptor Signaling (8/159)
Drug Metabolism (13) Metabolism of Xenobiotics by Cytochrome P450 (6/196)
Molecular Transport (25) Retinol Metabolism (4/64)
Small Molecule Biochemistry (30) Xenobiotic Metabolism Signaling (7/295)
Lipid Metabolism (22) Pyruvate Metabolism (4/139)
Top Upstream regulators Top Tox Lists
POR Nongenotoxic Hepatocarcinogenicity Biomarker Panel (5/22)
PPARA (Activated) Xenobiotic Metabolism Signaling (11/347)
AHR Aryl Hydrocarbon Receptor Signaling (8/156)
methylprednisolone CAR/RXR Activation (4/29)
NR1I3 (Activated) Glutathione Depletion - CYP Induc. and React. Metab. (3/12)
Top Tox Functions, Hepatotoxicity
Glutathione Depletion In Liver (3)
Hepatocellular Carcinoma (7)
Liver Hyperplasia/Hyperproliferation (7)
Liver Fibrosis (3)
Liver Steatosis (3)
Top Networks
Cell Cycle, Drug Metabolism, Glutathione Depletion In Liver (39)
Small Molecule Biochemistry, Amino Acid Metabolism, Energy Production (34)
Organ Development, Renal and Urological System Devel. and Func., Endocrine Sys. Disorders (21)
Amino Acid Metabolism, Small Molecule Biochemistry, Nutritional Disease (21)
Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry (19)
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Table A.2: Top biofunctions, canonical pathways, upstream regulators, tox lists and net-
works from Ingenuitys Core analysis of diﬀerentially expressed genes from those samples
with cellular change as histopathological ﬁnding. In Top Bio Functions and Top Tox
Functions, the number of genes or molecules are presented in the parenthesis. In Canoni-
cal Pathways and Top Tox Lists the ratio molecules in that pathway that meet the cut-oﬀ
criteria and the total number of molecules that make up that pathway is given. In Top Net-
works a network score representing the likelihood that the molecules are found by change
is shown.
Cellular change -group (274 diﬀerentially expressed genes)
Top Bio Function, Top Canonical Pathways
Molecular and Cellular
Functions
Lipid Metabolism (88) Xenobiotic Metabolism Signaling(21/295)
Molecular Transport (104) LPS/IL-1 Mediated Inhibition of RXR Func. (18/236)
Small Molecule Biochemistry (110) Aryl Hydrocarbon Receptor Signaling (15/159)
Carbohydrate Metabolism (59) Nitrogen Metabolism (8/119)
Vitamin and Mineral Metabolism (26) Glycerolipid Metabolism (12/156)
Top Upstream regulators Top Tox Lists
PPARA Xenobiotic Metabolism Signaling (28/347)
ACOX1 (Inhibited) Acute Renal Failure Panel (Rat) (13/62)
POR LPS/IL-1 Mediated Inhibition of RXR Func. (21/246)
dexamethasone Aryl Hydrocarbon Receptor Signaling (17/156)
pirinixic acid (Activated) Nongenotoxic Hepatocarcinog. Biomarker Panel (8/22)
Top Tox Functions, Hepatotoxicity
Liver Steatosis (19)
Liver Necrosis/Cell Death (4)
Liver Cholestasis (9)
Hepatocellular Carcinoma (23)
Liver Hyperplasia/Hyperproliferation (24)
Top Networks
Ophthalmic Disease, Hematological Disease, Metabolic Disease (42)
Behavior, Nervous System Development and Function, Endocrine System Dev. and Func. (40)
Drug Metabolism, Glutathione Depletion In Liver, Endocrine System Dev. and Func.(37)
Cell-To-Cell Signaling and Interaction, Tissue Development, Lipid Metabolism (33)
Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry (30)
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Table A.3: Top biofunctions, canonical pathways, upstream regulators, tox lists and net-
works from Ingenuitys Core analysis of diﬀerentially expressed genes from those samples
with cellular inﬁltration as histopathological ﬁnding. In Top Bio Functions and Top
Tox Functions, the number of genes or molecules are presented in the parenthesis. In
Canonical Pathways and Top Tox Lists the ratio molecules in that pathway that meet the
cut-oﬀ criteria and the total number of molecules that make up that pathway is given. In
Top Networks a network score representing the likelihood that the molecules are found by
change is shown.
Cellular inﬁltration -group (109 diﬀerentially expressed genes)
Top Bio Function, Top Canonical Pathways
Molecular and Cellular
Functions
Lipid Metabolism (38) Nitrogen Metabolism (6/119)
Small Molecule Biochemistry (46) Xenobiotic Metabolism Signaling (11/295)
Molecular Transport (44) LPS/IL-1 Mediated Inhibition of RXR Function (9/236)
Cellular Development (15) Metabolism of Xenobiotics by Cytochrome P450 (6/196)
Carbohydrate Metabolism (22) PXR/RXR Activation (5/88)
Top Upstream regulators Top Tox Lists
progesterone Xenobiotic Metabolism Signaling (14/347)
TO-901317 LPS/IL-1 Mediated Inhibition of RXR Function (10/246)
dexamethasone Nongenotoxic Hepatocarcinogenicity Biomarker Panel (4/22)
TNF CAR/RXR Activation (4/29)
POR NRF2-mediated Oxidative Stress Response (9/231)
Top Tox Functions, Hepatotoxicity
Glutathione Depletion In Liver (3)
Liver Cholestasis (5)
Liver Steatosis (8)
Hepatocellular Carcinoma (10)
Liver Hyperplasia/Hyperproliferation (10)
Top Networks
Lipid Metabolism, Small Molecule Biochemistry, Molecular Transport (46)
Hematological System Development and Function, Tissue Morphology, Cancer (36)
Amino Acid Metabolism, Small Molecule Biochemistry, Lipid Metabolism (28)
Small Molecule Biochemistry, Antigen Presentation, Cellular Movement (26)
Ophthalmic Disease, Respiratory Disease, Hereditary Disorder (26)
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Table A.4: Top biofunctions, canonical pathways, upstream regulators, tox lists and net-
works from Ingenuitys Core analysis of diﬀerentially expressed genes from those samples
with vacuolar degeneration as histopathological ﬁnding. In Top Bio Functions and Top
Tox Functions, the number of genes or molecules are presented in the parenthesis. In
Canonical Pathways and Top Tox Lists the ratio molecules in that pathway that meet the
cut-oﬀ criteria and the total number of molecules that make up that pathway is given. In
Top Networks a network score representing the likelihood that the molecules are found by
change is shown.
Vacuolar degeneration -group (880 diﬀerentially expressed genes)
Top Bio Function, Top Canonical Pathways
Molecular and Cellular
Functions
Lipid Metabolism (201) Fatty Acid Metabolism (26/183)
Small Molecule Biochemistry (253) LPS/IL-1 Mediated Inhibition of RXR Func. (34/236)
Molecular Transport (164) Arachidonic Acid Metabolism (21/206)
Energy Production (52) Glycerolipid Metabolism (19/156)
Vitamin and Mineral Metabolism (80) C21-Steroid Hormone Metabolism (8/66)
Top Upstream regulators Top Tox Lists
pirinixic acid (Activated) Fatty Acid Metabolism (28/123)
PPARA (Activated) LPS/IL-1 Mediated Inhibition of RXR Function (40/246)
methylprednisolone Cytochrome P450 Panel-Subst.:Fatty Acid (Mouse) (7/15)
cloﬁbrate (Activated) Cytochrome P450 Panel-Subst.:Fatty Acid (Rat) (7/12)
fenoﬁbrate (Activated) Acute Renal Failure Panel (Rat) (13/62)
Top Tox Functions, Hepatotoxicity
Liver Hyperplasia/Hyperproliferation (55)
Hepatocellular Carcinoma (54)
Liver Steatosis (32)
Liver Cholestasis (13)
Liver Damage (18)
Top Networks
Cell Morphology, Embryonic Development, Organ Development (51)
Lipid Metabolism, Small Molecule Biochemistry, Nucleic Acid Metabolism (38)
Endocrine System Development and Function, Lipid Metabolism, Small Molecule Biochemistry (35)
Cell Cycle, Nervous System Development and Function, Cell Death (35)
Cell Cycle, DNA Replication, Recombination, and Repair, Cellular Assembly and Organization (34)
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Figure A.1: PCA plots showing the separation between diﬀerent histopathological groups
(blue) and controls (green).
A. Appendixes 80
Figure A.2: PCA plots showing the separation between diﬀerent histopathological groups
colored according to the dose level and controls (controls). In each case, red indicated that
the rat was treated with high dose, blue indicates middle dose and green low dose.
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Figure A.3: PCA plots showing the separation between diﬀerent histopathological groups
colored according to the exposure time and controls (controls). In each case, red indicated
that the rat was treated with a certain dose for 28 days, orange indicates exposure time of
14 days, yellow of 7 days and green three days.
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Figure A.4: PCA plots showing the separation between diﬀerent histopathological groups
colored according to the severity of the histopathological ﬁnding and controls (controls).
In each case, red indicated that the ﬁnding was severe, orange indicates moderate ﬁnding,
yellow slight and green minimal.
A. Appendixes 83
Figure A.5: Myc-centered molecular networks of diﬀerent histopathological groups (form
upper left corner: hypertrophy, necrosis, cellular change, cellular inﬁltration, vacuolar de-
generation; images produced with Ingenuity) and of known hepatotoxic compounds (lowest
right corner, image borrowed from [39]. Red ang green represent up- and down-regulated
molecules, respectively.
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Table A.5: Most interesting genes, their p-values and log fold-changes in cellular change
-group.
Gene symbols log2 FC Adj. p-value Gene names
Ces2c 1,081834 4,05E-160 carboxylesterase 2C
Stac3 -1,94251 4,43E-140 SH3 and cysteine rich domain 3
Bmf -0,63551 5,29E-130 Bcl2 modifying factor
Aldh1a1 1,694144 2,55E-115 aldehyde dehydrogenase 1 family, mem-
ber A1
Pvrl3 -0,32822 2,55E-115 poliovirus receptor-related 3
Gsta5 1,779908 7,10E-114 glutathione S-transferase Yc2 subunit
Pc -0,37119 6,47E-111 pyruvate carboxylase
Slc46a1 -0,52542 4,66E-108 solute carrier family 46 (folate trans-
porter), member 1
Nt5e -0,40266 2,61E-104 5' nucleotidase, ecto
Apoa4 -0,50799 1,44E-102 apolipoprotein A-IV
Hsdl2 0,513135 1,35E-98 hydroxysteroid dehydrogenase like 2
Extl1 -0,50275 1,61E-98 exostoses (multiple)-like 1
Gulo -0,41146 4,00E-94 gulonolactone (L-) oxidase
Gucy1b2 -0,50865 4,63E-94 guanylate cyclase 1, soluble, beta 2
S1pr1 -0,35374 1,63E-93 sphingosine-1-phosphate receptor 1
R3hdm2 -0,67071 1,35E-91 R3H domain containing 2
Mgat4b -0,34883 1,67E-91 mannosyl (alpha-1,3-)-
glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme
B
Slc25a13 -0,31765 3,07E-90 solute carrier family 25, member 13
(citrin)
Abcc6 -0,29062 1,01E-89 ATP-binding cassette, subfamily C
(CFTR/MRP), member 6
Inhbe -0,62306 8,32E-89 inhibin beta E
Aldh1l2 -0,4426 9,11E-89 aldehyde dehydrogenase 1 family, mem-
ber L2
Inhbc -0,505 3,41E-85 inhibin beta C
Nhp2 0,332523 3,95E-85 NHP2 ribonucleoprotein homolog
(yeast)
Crem -0,42877 1,07E-83 cAMP responsive element modulator
Npdc1 0,397115 1,67E-82 neural proliferation, diﬀerentiation and
control, 1
Aig1 0,643931 1,85E-81 androgen-induced 1
Pklr -0,62173 3,35E-81 pyruvate kinase, liver and RBC
Coq10a -0,35931 3,48E-81 coenzyme Q10 homolog A (S. cere-
visiae)
Faah -0,31313 8,36E-81 fatty acid amide hydrolase
Aqp7 0,539105 1,52E-80 aquaporin 7
Rpp21 -0,29524 6,17E-80 ribonuclease P 21 subunit (human)
Cyp2t1 -0,4246 6,72E-80 cytochrome P450, family 2, subfamily
t, polypeptide 1
Ugt1a1 0,277882 5,14E-79 UDP glucuronosyltransferase 1 family,
polypeptide A1
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Table A.6: Most interesting genes, their p-values and log fold-changes in cellular inﬁl-
tration -group.
Gene symbols log2 FC Adj. p-value Gene names
Aldh1a1 1,472385 4,60E-131 aldehyde dehydrogenase 1 family, mem-
ber A1
Gsta5 1,445363 1,09E-125 glutathione S-transferase Yc2 subunit
Stac3 -1,27184 9,18E-112 SH3 and cysteine rich domain 3
R3hdm2 -0,54835 3,38E-107 R3H domain containing 2
Ces2c 0,839079 3,38E-107 carboxylesterase 2C
Ephx1 0,32881 2,84E-102 epoxide hydrolase 1, microsomal
App 0,40395 1,37E-98 amyloid beta (A4) precursor protein
Oat -0,61323 4,36E-93 ornithine aminotransferase (gyrate at-
rophy)
Bmf -0,36215 6,52E-93 Bcl2 modifying factor
Akr7a3 0,607537 2,27E-87 aldo-keto reductase family 7, member
A3 (aﬂatoxin aldehyde reductase)
Cyp2t1 -0,28364 4,74E-79 cytochrome P450, family 2, subfamily
t, polypeptide 1
Extl1 -0,31185 1,64E-77 exostoses (multiple)-like 1
Dexi -0,29714 1,24E-75 dexamethasone-induced transcript
Cd276 0,277609 3,03E-75 Cd276 molecule
Apoa4 -0,40647 1,86E-73 apolipoprotein A-IV
Inhbe -0,36692 2,17E-73 inhibin beta E
Mtmr7 -0,63384 2,75E-72 myotubularin related protein 7
Npdc1 0,29424 2,33E-71 neural proliferation, diﬀerentiation and
control, 1
Pklr -0,38811 6,33E-70 pyruvate kinase, liver and RBC
Pter 0,30234 3,64E-69 phosphotriesterase related
Gstm3 0,751076 1,14E-68 glutathione S-transferase mu 3
Prodh -0,28227 3,96E-68 proline dehydrogenase
Sez6 -0,55664 3,61E-67 seizure related 6 homolog (mouse)
Hsdl2 0,298849 8,07E-67 hydroxysteroid dehydrogenase like 2
Zdhhc2 0,413422 1,35E-66 zinc ﬁnger, DHHC-type containing 2
Snx10 0,331591 2,58E-66 sorting nexin 10
LOC100363310 0,286244 1,44E-65 hypothetical protein LOC100363310
Lgals3 0,389899 2,25E-63 lectin, galactoside-binding, soluble, 3
Hal -0,33319 3,13E-63 histidine ammonia lyase
Car3 -0,51823 3,79E-63 carbonic anhydrase 3
Dak -0,29096 1,52E-62 dihydroxyacetone kinase 2 homolog (S.
cerevisiae)
Nox4 -0,58841 1,49E-61 NADPH oxidase 4
Asns 0,545342 3,19E-61 asparagine synthetase
Vnn1 0,601442 7,52E-61 vanin 1
LOC367746 -0,69962 1,14E-60 similar to Spindlin-like protein 2
(SPIN-2)
Epcam 0,341203 2,93E-57 epithelial cell adhesion molecule
Ugt2b1 0,62223 3,50E-55 UDP glucuronosyltransferase 2 family,
polypeptide B1
Gpx2 0,484635 1,90E-53 glutathione peroxidase 2
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Table A.7: Most interesting genes, their p-values and log fold-changes in hypertrophy
-group.
Gene symbols log2 FC Adj. p-value Gene names
Gsta5 2,752421 0 glutathione S-transferase Yc2 subunit
Ces2c 1,782927 0 carboxylesterase 2C
Aldh1a1 2,509542 0 aldehyde dehydrogenase 1 family, mem-
ber A1
Ugt1a1 0,505014 0,00E+00 UDP glucuronosyltransferase 1 family,
polypeptide A1
Ephx1 0,617107 4,41E-276 epoxide hydrolase 1, microsomal
Pc -0,45947 1,39E-257 pyruvate carboxylase
Hibch 0,454164 2,71E-247 3-hydroxyisobutyryl-Coenzyme A hy-
drolase
Mgst2 0,529633 1,75E-239 microsomal glutathione S-transferase 2
Gstm4 0,42989 3,80E-234 glutathione S-transferase mu 4
Gsr 0,51944 5,18E-214 glutathione reductase
App 0,541518 6,67E-207 amyloid beta (A4) precursor protein
Pvrl3 -0,34273 1,48E-206 poliovirus receptor-related 3
Pir 0,88573 9,77E-202 pirin (iron-binding nuclear protein)
Cltb 0,290364 9,13E-199 clathrin, light chain (Lcb)
Akr7a3 1,154102 1,37E-196 aldo-keto reductase family 7, member
A3 (aﬂatoxin aldehyde reductase)
Dexi -0,48441 7,63E-196 dexamethasone-induced transcript
Ugt2b1 1,379859 7,44E-181 UDP glucuronosyltransferase 2 family,
polypeptide B1
Keg1 0,688626 2,12E-175 kidney expressed gene 1
Rexo2 0,276733 2,95E-166 REX2, RNA exonuclease 2 homolog (S.
cerevisiae)
Hal -0,49179 7,13E-164 histidine ammonia lyase
LOC498606 0,308457 1,25E-162 hypothetical protein LOC498606
Cyp3a23/3a1 0,403249 1,95E-162 cytochrome P450, family 3, subfamily
a, polypeptide 23/polypeptide 1
H1f0 -0,38542 5,91E-161 H1 histone family, member 0
Csrp1 -0,49648 9,91E-159 cysteine and glycine-rich protein 1
Pter 0,454702 1,14E-157 phosphotriesterase related
Stac3 -1,34021 2,40E-154 SH3 and cysteine rich domain 3
Zdhhc2 0,636033 4,15E-154 zinc ﬁnger, DHHC-type containing 2
Nap1l1 0,275011 5,86E-153 nucleosome assembly protein 1-like 1
R3hdm2 -0,61979 2,63E-151 R3H domain containing 2
Cyp2t1 -0,39786 3,15E-150 cytochrome P450, family 2, subfamily
t, polypeptide 1
Oat -0,76416 9,10E-149 ornithine aminotransferase (gyrate at-
rophy)
Bmf -0,39981 1,59E-147 Bcl2 modifying factor
LOC100363310 0,427139 2,83E-147 hypothetical protein LOC100363310
Gstm3 1,023933 8,94E-147 glutathione S-transferase mu 3
Cyp2j4 0,546376 4,12E-146 cytochrome P450, family 2, subfamily
j, polypeptide 4
Car1 -0,47165 2,97E-141 carbonic anhydrase 1
Pklr -0,59184 1,37E-140 pyruvate kinase, liver and RBC
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Table A.8: Most interesting genes, their p-values and log fold-changes in necrosis -group.
Gene symbols log2 FC Adj. p-value Gene names
Stac3 -1,11662 1,76E-73 SH3 and cysteine rich domain 3
Ces2c 0,746815 2,59E-69 carboxylesterase 2C
Gsta5 1,172307 4,48E-49 glutathione S-transferase Yc2 subunit
Ccng1 0,431957 3,69E-47 cyclin G1
Slc46a1 -0,3055 3,18E-44 solute carrier family 46 (folate trans-
porter), member 1
Oat -0,51692 3,90E-43 ornithine aminotransferase (gyrate at-
rophy)
Extl1 -0,32438 8,60E-43 exostoses (multiple)-like 1
Bmf -0,30689 1,35E-42 Bcl2 modifying factor
Akr7a3 0,501073 1,97E-41 aldo-keto reductase family 7, member
A3 (aﬂatoxin aldehyde reductase)
Ephx1 0,277169 4,38E-41 epoxide hydrolase 1, microsomal
R3hdm2 -0,45626 6,00E-41 R3H domain containing 2
Aldh1a1 0,999665 1,43E-38 aldehyde dehydrogenase 1 family, mem-
ber A1
Cyp1a1 0,386277 4,91E-38 cytochrome P450, family 1, subfamily
a, polypeptide 1
Apoa4 -0,32915 8,37E-38 apolipoprotein A-IV
Gstm3 0,643146 9,43E-38 glutathione S-transferase mu 3
Eci1 0,341017 2,67E-36 enoyl-Coenzyme A delta isomerase 1
Aqp7 0,344713 8,52E-36 aquaporin 7
Mdm2 0,320954 1,29E-34 Mdm2 p53 binding protein homolog
(mouse)
Id1 0,338313 1,29E-34 inhibitor of DNA binding 1
Hsdl2 0,32662 5,14E-34 hydroxysteroid dehydrogenase like 2
Slc22a8 -0,45826 2,09E-33 solute carrier family 22 (organic anion
transporter), member 8
Lgals3 0,378142 2,50E-33 lectin, galactoside-binding, soluble, 3
Csrp1 -0,30463 3,34E-33 cysteine and glycine-rich protein 1
Gdf15 0,36041 2,03E-32 growth diﬀerentiation factor 15
Pklr -0,35306 2,67E-31 pyruvate kinase, liver and RBC
Sez6 -0,52018 5,76E-31 seizure related 6 homolog (mouse)
Car3 -0,4548 6,82E-30 carbonic anhydrase 3
Hapln3 0,314583 4,83E-28 hyaluronan and proteoglycan link pro-
tein 3
Aig1 0,329081 9,77E-28 androgen-induced 1
Inhbe -0,30328 2,71E-27 inhibin beta E
Ech1 0,263608 9,00E-27 enoyl coenzyme A hydratase 1, peroxi-
somal
Rbp7 0,512751 6,41E-26 retinol binding protein 7, cellular
Olr59 -0,3263 8,49E-25 olfactory receptor 59
Cela1 -0,39367 1,10E-24 chymotrypsin-like elastase family,
member 1
Serpina7 0,662639 1,14E-23 serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin),
member 7
Nox4 -0,49581 8,64E-20 NADPH oxidase 4
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Table A.9: Most interesting genes, their p-values and log fold-changes in vacuolar de-
generation -group.
Gene symbols log2 FC Adj. p-value Gene names
Ces2c 1,816776 0 carboxylesterase 2C
Ugt1a1 0,663839 0 UDP glucuronosyltransferase 1 family,
polypeptide A1
Stac3 -3,23725 7,07E-308 SH3 and cysteine rich domain 3
Aldh1a1 2,791489 1,19E-295 aldehyde dehydrogenase 1 family, mem-
ber A1
Acaa1a 1,478236 6,32E-266 acetyl-Coenzyme A acyltransferase 1A
Cyp2t1 -0,87097 7,42E-264 cytochrome P450, family 2, subfamily
t, polypeptide 1
Pvrl3 -0,64039 6,40E-259 poliovirus receptor-related 3
Acot2 1,464696 3,64E-258 acyl-CoA thioesterase 2
Vnn1 2,920794 4,61E-256 vanin 1
Zdhhc2 1,115911 2,04E-252 zinc ﬁnger, DHHC-type containing 2
Hsdl2 1,520351 7,36E-251 hydroxysteroid dehydrogenase like 2
Npdc1 0,783117 1,23E-249 neural proliferation, diﬀerentiation and
control, 1
Extl1 -0,88581 1,51E-247 exostoses (multiple)-like 1
Aig1 2,32903 1,71E-241 androgen-induced 1
Apoa4 -2,00383 4,41E-232 apolipoprotein A-IV
Csrp1 -0,92948 1,10E-231 cysteine and glycine-rich protein 1
Hibch 0,806046 1,96E-230 3-hydroxyisobutyryl-Coenzyme A hy-
drolase
Eci1 1,434926 8,06E-228 enoyl-Coenzyme A delta isomerase 1
Nap1l1 0,629533 2,56E-227 nucleosome assembly protein 1-like 1
Gulo -0,59395 1,13E-226 gulonolactone (L-) oxidase
Gls2 -0,58743 2,78E-222 glutaminase 2 (liver, mitochondrial)
Hmgcl 0,672089 2,08E-217 3-hydroxymethyl-3-methylglutaryl-
Coenzyme A lyase
Cyp2j4 1,147857 1,34E-216 cytochrome P450, family 2, subfamily
j, polypeptide 4
Crat 1,635456 1,13E-215 carnitine acetyltransferase
Aqp7 2,050913 1,06E-214 aquaporin 7
Ehhadh 1,466583 2,11E-214 enoyl-Coenzyme A, hydratase/3-
hydroxyacyl Coenzyme A dehydroge-
nase
Hal -0,95475 8,15E-214 histidine ammonia lyase
Ech1 1,524938 9,89E-214 enoyl coenzyme A hydratase 1, peroxi-
somal
Mgat4b -0,72416 3,03E-212 mannosyl (alpha-1,3-)-
glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme
B
Me1 1,720769 1,46E-211 malic enzyme 1, NADP(+)-dependent,
cytosolic
Cyp4a1 1,46288 1,46E-211 cytochrome P450, family 4, subfamily
a, polypeptide 1
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Table A.10: 50 ﬁrst GO terms and corresponding p-values for cellular change -group.
GO term (BP) p-value
cellular ketone metabolic process 5,38E-24
organic acid metabolic process 1,41E-23
carboxylic acid metabolic process 2,34E-23
oxoacid metabolic process 2,34E-23
lipid metabolic process 2,59E-21
monocarboxylic acid metabolic process 3,63E-20
response to organic substance 4,09E-19
response to hormone stimulus 8,09E-17
response to endogenous stimulus 4,12E-16
fatty acid metabolic process 5,68E-16
cellular lipid metabolic process 2,93E-15
response to external stimulus 3,11E-14
response to steroid hormone stimulus 6,59E-14
cellular response to chemical stimulus 7,71E-14
response to drug 2,92E-13
response to extracellular stimulus 3,66E-13
response to peptide hormone stimulus 1,97E-12
response to nutrient levels 4,98E-12
small molecule biosynthetic process 5,50E-12
cellular response to organic substance 2,53E-11
response to glucocorticoid stimulus 6,00E-11
oxidation-reduction process 7,79E-11
lipid biosynthetic process 1,32E-10
aging 1,61E-10
response to corticosteroid stimulus 1,94E-10
response to abiotic stimulus 5,45E-10
steroid metabolic process 1,28E-09
regulation of lipid biosynthetic process 1,70E-09
response to nutrient 2,57E-09
small molecule metabolic process 2,75E-09
response to organic cyclic compound 3,61E-09
regulation of lipid metabolic process 8,79E-09
response to stress 8,92E-09
cellular response to hormone stimulus 2,37E-08
organic acid biosynthetic process 2,44E-08
carboxylic acid biosynthetic process 2,44E-08
cellular amine metabolic process 2,76E-08
alcohol metabolic process 3,91E-08
response to toxin 6,20E-08
secondary metabolic process 7,83E-08
amine metabolic process 1,12E-07
response to inorganic substance 1,96E-07
fatty acid biosynthetic process 2,41E-07
cellular aromatic compound metabolic process 2,56E-07
cellular response to endogenous stimulus 2,86E-07
cellular response to peptide hormone stimulus 3,29E-07
very long-chain fatty acid metabolic process 5,09E-07
response to insulin stimulus 5,12E-07
metabolic process 7,42E-07
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Table A.11: 50 ﬁrst GO terms and corresponding p-values for cellular inﬁltration -group.
GO term (BP) p-value
carboxylic acid metabolic process 6,81E-16
oxoacid metabolic process 6,81E-16
organic acid metabolic process 1,26E-15
cellular ketone metabolic process 1,83E-15
response to organic substance 1,24E-13
response to endogenous stimulus 5,35E-13
response to external stimulus 6,24E-12
monocarboxylic acid metabolic process 3,35E-11
response to hormone stimulus 2,16E-10
cellular response to chemical stimulus 2,96E-10
response to drug 6,63E-09
response to extracellular stimulus 7,46E-09
cellular response to organic substance 9,80E-09
response to nutrient levels 1,59E-08
response to stress 5,00E-08
response to nutrient 6,72E-08
fatty acid metabolic process 7,47E-08
cellular amino acid metabolic process 1,23E-07
lipid metabolic process 3,05E-07
cell death 5,52E-07
death 6,07E-07
cellular amine metabolic process 6,68E-07
response to chemical stimulus 7,75E-07
amine metabolic process 1,46E-06
apoptosis 1,56E-06
cellular response to hormone stimulus 1,60E-06
programmed cell death 1,99E-06
response to steroid hormone stimulus 2,15E-06
regulation of cell death 2,31E-06
negative regulation of catalytic activity 2,36E-06
cellular response to endogenous stimulus 2,95E-06
regulation of apoptosis 3,15E-06
regulation of programmed cell death 3,83E-06
response to vitamin 4,16E-06
small molecule biosynthetic process 4,24E-06
response to organic cyclic compound 5,75E-06
response to peptide hormone stimulus 5,97E-06
catabolic process 6,08E-06
regulation of catalytic activity 8,02E-06
phenylpropanoid metabolic process 1,06E-05
organic acid biosynthetic process 1,20E-05
carboxylic acid biosynthetic process 1,20E-05
regulation of response to external stimulus 1,36E-05
response to other organism 1,54E-05
secondary metabolic process 1,54E-05
negative regulation of cell death 2,37E-05
negative regulation of biological process 2,38E-05
regulation of biological quality 2,38E-05
aging 2,39E-05
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Table A.12: 50 ﬁrst GO terms and corresponding p-values for hypertrophy -group.
GO term (BP) p-value
carboxylic acid metabolic process 1,13E-31
oxoacid metabolic process 1,13E-31
organic acid metabolic process 3,41E-31
cellular ketone metabolic process 6,64E-31
monocarboxylic acid metabolic process 2,81E-24
fatty acid metabolic process 1,79E-18
lipid metabolic process 4,01E-13
cellular lipid metabolic process 2,07E-11
organic acid biosynthetic process 9,26E-11
carboxylic acid biosynthetic process 9,26E-11
cellular amino acid metabolic process 1,38E-10
response to organic substance 2,79E-10
response to extracellular stimulus 6,31E-10
response to endogenous stimulus 7,74E-10
response to nutrient levels 1,01E-09
cellular amine metabolic process 2,94E-09
response to hormone stimulus 4,03E-09
small molecule biosynthetic process 1,04E-08
amine metabolic process 1,54E-08
small molecule metabolic process 2,29E-08
oxidation-reduction process 2,88E-08
response to external stimulus 3,16E-08
metabolic process 3,36E-08
response to xenobiotic stimulus 3,37E-08
response to steroid hormone stimulus 1,18E-07
response to nutrient 1,42E-07
xenobiotic metabolic process 2,30E-07
cellular response to xenobiotic stimulus 2,30E-07
cellular response to endogenous stimulus 3,16E-07
cellular response to chemical stimulus 4,53E-07
cellular response to hormone stimulus 4,66E-07
fatty acid biosynthetic process 5,33E-07
response to drug 1,03E-06
cellular metabolic process 1,78E-06
cellular response to organic substance 2,97E-06
lipid biosynthetic process 4,19E-06
xenobiotic catabolic process 7,22E-06
glutathione metabolic process 7,89E-06
organic acid catabolic process 8,39E-06
carboxylic acid catabolic process 8,39E-06
response to stress 9,16E-06
secondary metabolic process 1,14E-05
long-chain fatty acid metabolic process 1,38E-05
very long-chain fatty acid metabolic process 1,51E-05
peptide metabolic process 1,90E-05
cellular modiﬁed amino acid metabolic process 1,97E-05
cellular response to peptide hormone stimulus 2,20E-05
response to glucocorticoid stimulus 2,25E-05
pyruvate biosynthetic process 2,62E-05
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Table A.13: 50 ﬁrst GO terms and corresponding p-values for necrosis -group.
GO term (BP) p-value
organic acid metabolic process 2,94E-14
carboxylic acid metabolic process 1,30E-13
oxoacid metabolic process 1,30E-13
cellular ketone metabolic process 2,93E-13
monocarboxylic acid metabolic process 4,01E-13
lipid metabolic process 5,04E-10
fatty acid metabolic process 3,60E-09
response to organic substance 2,62E-08
response to stress 4,81E-07
response to steroid hormone stimulus 4,95E-07
response to toxin 6,23E-07
response to external stimulus 9,18E-07
response to endogenous stimulus 1,19E-06
response to organic cyclic compound 2,45E-06
aging 2,88E-06
response to drug 4,44E-06
response to extracellular stimulus 4,81E-06
cellular lipid metabolic process 6,59E-06
response to estrogen stimulus 1,05E-05
response to other organism 1,97E-05
response to hormone stimulus 2,69E-05
oxidation-reduction process 3,28E-05
response to nutrient 3,47E-05
cellular response to chemical stimulus 3,67E-05
response to biotic stimulus 4,43E-05
secondary metabolic process 4,48E-05
response to nutrient levels 5,44E-05
toxin metabolic process 6,65E-05
response to abiotic stimulus 6,87E-05
response to bacterium 9,61E-05
multi-organism process 9,85E-05
response to vitamin 0,000176
vitamin metabolic process 0,000227
response to glucocorticoid stimulus 0,00027
cellular response to organic substance 0,000292
response to wounding 0,000306
response to vitamin A 0,000308
retinoic acid metabolic process 0,000361
response to corticosteroid stimulus 0,000387
response to iron(III) ion 0,000416
cellular response to radiation 0,000495
response to inorganic substance 0,000555
vitamin biosynthetic process 0,000594
response to chemical stimulus 0,000618
cellular hormone metabolic process 0,00066
endothelial cell chemotaxis 0,000689
response to oxidative stress 0,000836
regulation of anti-apoptosis 0,000871
response to ethanol 0,000959
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Table A.14: 50 ﬁrst GO terms and corresponding p-values for vacuolar degeneration -group.
GO term (BP) p-value
cellular ketone metabolic process 2,66E-34
organic acid metabolic process 1,62E-33
carboxylic acid metabolic process 4,52E-33
oxoacid metabolic process 4,52E-33
monocarboxylic acid metabolic process 1,76E-26
fatty acid metabolic process 5,08E-22
lipid metabolic process 1,03E-20
cellular lipid metabolic process 1,41E-17
response to organic substance 6,19E-17
oxidation-reduction process 2,05E-16
metabolic process 4,00E-15
response to external stimulus 1,98E-14
response to endogenous stimulus 1,62E-13
small molecule metabolic process 3,24E-13
response to stress 8,86E-13
response to extracellular stimulus 1,72E-12
response to hormone stimulus 2,92E-12
catabolic process 6,52E-12
response to nutrient levels 1,42E-11
cellular metabolic process 6,22E-11
cellular catabolic process 7,85E-11
cellular response to chemical stimulus 1,44E-10
cellular amine metabolic process 1,59E-10
very long-chain fatty acid metabolic process 6,13E-10
cellular lipid catabolic process 7,75E-10
amine metabolic process 1,23E-09
response to nutrient 1,79E-09
organic acid biosynthetic process 1,80E-09
carboxylic acid biosynthetic process 1,80E-09
small molecule biosynthetic process 3,55E-09
cellular amino acid metabolic process 3,65E-09
lipid catabolic process 3,85E-09
alcohol metabolic process 4,43E-09
arachidonic acid metabolic process 5,77E-09
protein activation cascade 6,64E-09
organic acid catabolic process 7,09E-09
carboxylic acid catabolic process 7,09E-09
primary metabolic process 7,24E-09
organic ether metabolic process 8,30E-09
organic substance transport 1,10E-08
lipid biosynthetic process 1,26E-08
regulation of lipid metabolic process 1,28E-08
response to drug 1,61E-08
cellular response to organic substance 2,30E-08
response to steroid hormone stimulus 2,47E-08
fatty acid oxidation 2,52E-08
complement activation 3,02E-08
lipid oxidation 4,02E-08
small molecule catabolic process 8,55E-08
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Figure A.6: Boxplots showing deviation of gene expression values of chosen genes in controls
(green) and samples (blue) belonging to cellular change (left), cellular inﬁltration (middle)
and vacuolar degeneration (right) groups. (The bottom and top of the box are the 25th and
75th percentile, the band near the middle of the box is the 50th percentile, and the whiskers
show the most extreme data points which are no more than 1.5 times the interquartile range
from the box. Data points beyond this range (outliers) are marked with circles.
